REVIEW

Orexin/hypocretin receptor signalling: a functional perspective

C S Leonard¹ and J P Kukkonen²

¹Department of Physiology, New York Medical College, Valhalla, NY, USA, and ²Biochemistry and Cell Biology, Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland

Correspondence

Christopher S Leonard,
Department of Physiology, New
York Medical College, Valhalla,
NY 10595, USA. E-mail:
chris_leonard@nymc.edu;
Jyrki P Kukkonen, Department
of Veterinary Biosciences, PO
Box 66, FIN-00014 University
of Helsinki, Finland. E-mail:
jyrki.kukkonen@helsinki.fi

Keywords

orexin; hypocretin; neuron;
adrenal gland; adipose tissue;
depolarization; plasticity; cell
death; hormone release; second
messenger

Received

14 January 2013

Revised

17 June 2013

Accepted

3 July 2013

Multiple homeostatic systems are regulated by orexin (hypocretin) peptides and their two known GPCRs. Activation of orexin receptors promotes waking and is essential for expression of normal sleep and waking behaviour, with the sleep disorder narcolepsy resulting from the absence of orexin signalling. Orexin receptors also influence systems regulating appetite/metabolism, stress and reward, and are found in several peripheral tissues. Nevertheless, much remains unknown about the signalling pathways and targets engaged by native receptors. In this review, we integrate knowledge about the orexin receptor signalling capabilities obtained from studies in expression systems and various native cell types (as presented in Kukkonen and Leonard, this issue of *British Journal of Pharmacology*) with knowledge of orexin signalling in different tissues. The tissues reviewed include the CNS, the gastrointestinal tract, the pituitary gland, pancreas, adrenal gland, adipose tissue and the male reproductive system. We also summarize the findings in different native and recombinant cell lines, especially focusing on the different cascades in CHO cells, which is the most investigated cell line. This reveals that while a substantial gap exists between what is known about orexin receptor signalling and effectors in recombinant systems and native systems, mounting evidence suggests that orexin receptor signalling is more diverse than originally thought. Moreover, rather than being restricted to orexin receptor 'overexpressing' cells, this signalling diversity may be utilized by native receptors in a site-specific manner.

LINKED ARTICLES

This article is part of a themed section on Orexin Receptors. To view the other articles in this section visit <http://dx.doi.org/10.1111/bph.2014.171.issue-2>

Abbreviations

2-AG, 2-arachidonoylglycerol; AA, arachidonic acid; (s)AHP, (slow) afterhyperpolarization; AR42J, a rat pancreatic acinar tumour cell line; BAPTA, 1,2-bis(O-aminophenoxy)ethane-*N,N,N',N'*-tetraacetic acid; Caco-2, HT29-D4, LoVo and SW480, human colon carcinoma cell lines, cPLA₂, cytosolic (Ca²⁺-sensitive) phospholipase A₂; DGL, DAG lipase; H-current, a non-selective cation current mediated by hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels; HSD3B2, 3β-hydroxysteroid dehydrogenase; IMR-32 and SK-N-MC, human neuroblastoma cell lines; IP₃, inositol-1,4,5-trisphosphate; *I*_{SAHP}, sAHP current; Kir channels, inward rectifier K⁺ channels; MEF, mouse embryonic fibroblast; MEK1, MAPK/ERK kinase 1; NCX, Na⁺/Ca²⁺-exchanger; neuro-2a, a mouse neuroblastoma cell line; nPKC, novel PKC; NSCC, non-selective cation channel; OX₁ and OX₂, OX₁ and OX₂ orexin receptors, respectively; PC12, a rat pheochromocytoma cell line; PIP, phosphatidylinositol-4-phosphate; PIP₂, phosphatidylinositol-4,5-bisphosphate; TRP (channel), transient receptor potential (channel); VGCC, voltage-gated Ca²⁺ channel

Introduction

The landmark discoveries of the orexin (hypocretin) peptides (orexin-A and orexin-B) and their two known GPCRs (OX₁

and OX₂ receptors) in 1998 (de Lecea *et al.*, 1998; Sakurai *et al.*, 1998) set the stage for a new understanding of the brain's arousal system and the sleep disorder narcolepsy – a disorder characterized by excessive sleepiness, sleep attacks

and the sudden loss of postural muscle tone (cataplexy) (for review, Siegel and Boehmer, 2006). Beyond arousal, orexins are implicated in the regulation of appetite, metabolism, stress, reward and autonomic function (for review, see Carter *et al.*, 2009; Sharf *et al.*, 2010; Girault *et al.*, 2012; Nattie and Li, 2012), suggesting that these peptides work globally to organize and adjust homeostatic responses (see Li and de Lecea, 2013). In spite of these advances, many questions remain concerning how the orexin system operates. One critical question relates to the nature of the signalling cascades and effectors utilized by native orexin receptors. The answer to this question is important both from a functional perspective and from the perspective of developing new pharmacotherapeutics focused on these receptors (see Winrow and Renger, 2013) or their signalling pathways. As indicated in our sister review (Kukkonen and Leonard, 2013), the signalling of orexin receptors is multifaceted and complex. However, the widest spectrum of responses is seen in recombinant cell lines, like CHO. Do these diverse responses result from receptor overexpression or can native orexin receptors also couple to so many signal cascades? And if so, are all the cascades utilized in all tissues or is there specificity perhaps based on specific tissue needs? This review summarizes what is known about native orexin receptor signalling in the brain and peripheral tissues and aims at answering these questions. We also try to correlate orexin responses with particular orexin receptor subtypes. As orexin receptor identification by antibodies or by use of a reputedly selective agonist is unreliable (reviewed in Kukkonen, 2012; 2013), we have focused on studies utilizing mRNA detection, selective receptor antagonists and receptor knockout data.

CNS

The CNS is the most important orexin target tissue as orexin peptides are synthesized in the hypothalamus by a small group of neurons (de Lecea *et al.*, 1998; Sakurai *et al.*, 1998) with axons that are widely distributed in the CNS (Peyron *et al.*, 1998; Nambu *et al.*, 1999; van den Pol, 1999). Consequently, CNS neurons are the most extensively investigated native cells for orexin responses. However, CNS neurons are not a single cell type but represent an unknown number of different subtypes, with multiple subtypes often interdigitated within the same structures. This, of course, makes biochemical and pharmacological analysis difficult or impossible, and therefore, we have focused primarily on single cell electrophysiology and Ca^{2+} imaging approaches *in vitro*, mainly in brain slices, which have cellular resolution.

Based on *in situ* hybridization, both known orexin receptors are distributed throughout the CNS, each having a different, yet overlapping, pattern (Trivedi *et al.*, 1998; Marcus *et al.*, 2001). Moreover, several single-cell RT-PCR studies indicate that, at least in some places, mRNA for both receptors can be co-expressed (Eriksson *et al.*, 2001; Brown *et al.*, 2002; Korotkova *et al.*, 2003; van den Top *et al.*, 2003). By comparing the published distribution of orexin receptor mRNA with the results from *in vitro* recordings, it is clear that there is excellent correspondence between receptor mRNA expression and functional receptors, as determined by the presence of postsynaptic orexin responses (see Supporting Information

Table S1). It is also clear that while the response to orexin application has been tested for many cell groups, there are regions expressing modest to high levels of mRNA that have not yet been studied (e.g. tectum, intergeniculate leaflet and numerous hypothalamic nuclei; compare Supporting Information Table S1 to Marcus *et al.*, 2001, table 1). There are also regions where mRNA was not noted but where neurons have functional receptors (e.g. thalamic parafascicular nucleus, area postrema and sublaterodorsal nucleus) where more detailed *in situ* analysis is needed (see Mieda *et al.*, 2011). Finally, there are a couple of regions where neurons show direct postsynaptic responses to applied orexin but have mRNA levels appearing no higher than background (e.g. substantia nigra pars reticulata, medial dorsal nucleus of the thalamus), suggesting that functional receptors may be present in neurons having low mRNA levels or in regions with low densities of expressing neurons. Thus, it is possible that functionally important groups of orexin-responding neurons have not yet been detected.

Orexin receptor actions in the CNS

So far, for neurons that respond to exogenous orexin-A or orexin-B with a change in membrane potential, orexins produce a slow and long-lasting depolarization that can be large enough to initiate firing, or – if the neuron is already firing – to increase its firing rate. Thus, orexins are universally considered excitatory neuropeptides because their receptors couple to effectors that produce depolarization.

Although there are a few cases where the effectors underlying these depolarizations have been identified at a molecular level (Kukkonen and Leonard, 2013), in most cases, depolarization has been attributed to three categories of action: (i) closure of K^+ channels active at rest (Figure 1A; Horvath *et al.*, 1999; Ivanov and Aston-Jones, 2000; Brown *et al.*, 2001; Hwang *et al.*, 2001; Bayer *et al.*, 2002; Grabauskas and Moises, 2003; Hoang *et al.*, 2003; 2004; van den Top *et al.*, 2003; Yang and Ferguson, 2003; Yang *et al.*, 2003; Bayer *et al.*, 2004; Wu *et al.*, 2004; Murai and Akaike, 2005; Bisetti *et al.*, 2006; Govindaiah and Cox, 2006; Huang *et al.*, 2006; Kolaj *et al.*, 2008; Doroshenko and Renaud, 2009; Zhang *et al.*, 2010; 2011); (ii) activation of an electrogenic sodium-calcium exchanger (NCX) (Figure 1B; Eriksson *et al.*, 2001; Wu *et al.*, 2002; 2004; Burdakov *et al.*, 2003; Acuna-Goycolea and van den Pol, 2009; Zhang *et al.*, 2011); and (iii) the activation of non-selective cation channels (NSCCs) (Figure 1C; Eriksson *et al.*, 2001; Hwang *et al.*, 2001; Brown *et al.*, 2002; Burlet *et al.*, 2002; Liu *et al.*, 2002; Wu *et al.*, 2002; 2004; Yang and Ferguson, 2002; Yang and Ferguson, 2003; Huang *et al.*, 2006).

As noted in Kukkonen and Leonard (2013), closure of K^+ channels active at rest has been relatively straightforward to demonstrate following application of orexin. For example, the membrane depolarization produced by orexin in layer 6b neurons (Bayer *et al.*, 2004) results from a reduction in membrane current that has a reversal potential that shifts in a Nernstian manner with the K^+ equilibrium potential (Figure 1A). In contrast, the distinction between currents arising from the NCX and NSCC are more problematic, especially in the absence of detailed biophysical analyses because these currents can have similar reversal potentials, are difficult to isolate from other membrane currents, are lacking

Figure 1

Orexin-mediated depolarizations in the CNS. (A) Orexins close leak-like K^+ channels. The orexin-B-mediated (100 nM) depolarization in layer 6b neocortical pyramidal neurons, which causes firing, is associated with an increase in membrane resistance (note the larger negative-going voltage deflections produced by constant current pulses during the depolarization (A₁). The I - V curve for the orexin-activated current reverses near the predicted K^+ equilibrium potential in an extracellular $[K^+]$ of 6.25 mM (upper I - V curve) and 12 mM (lower I - V curve) (A₂). The inset shows the mean reversal potential measured at each extracellular $[K^+]$. (B) Orexins stimulate electrogenic NCX. Orexin-A produces a suprathreshold depolarization in type C arcuate nucleus neurons of the hypothalamus (B₁). The depolarizing current is insensitive to lowering extracellular $[Ca^{2+}]$ (not shown) but is completely blocked by strong buffering of intracellular Ca^{2+} (BAPTA, 10 mM), consistent with it being triggered by the release of Ca^{2+} from intracellular stores (B₂). The reversal potential of the orexin-activated exchanger current shifts with changes of Na^+ and Ca^{2+} gradients (B₃). (C) Orexins activate a 'noisy' non-selective cation current that is not reduced by low extracellular $[Ca^{2+}]$ or strong buffering of intracellular $[Ca^{2+}]$. The orexin-A-activated current in dorsal raphe neurons was initiated, but was almost absent in low extracellular $[Na^+]$ (26 mM; NMDG). The current was reinstated by switching back to normal extracellular $[Na^+]$ (150 mM; C₁). The reversal potential of this cation current is near 0 mV in normal extracellular $[Na^+]$ (C₂, upper subfigure) but shifts to near -60 mV in low extracellular $[Na^+]$ (C₂, lower subfigure). Subfigures (A), (B) and (C) are adapted from Bayer *et al.* (2004); Burdakov *et al.* (2003); and Brown *et al.* (2002), respectively and are reproduced with permission.

highly selective antagonists (Clapham, 2003; Török, 2007; Numata *et al.*, 2011) and can be interdependent (Rosker *et al.*, 2004; Louhivuori *et al.*, 2010). Further complicating the matter, simultaneous closure of K^+ channels and activation of one or both of the other effectors appears to underlie orexin actions in some neurons. Thus, we feel that identification of either NCX or NSCCs as targets for orexin receptor activation in most neurons should be considered provisional. Nevertheless, in some neurons, distinction between a NCX and a NSCC underlying the orexin-mediated depolarization appears warranted (see Supporting Information Table S1; Figure 1B,C). For example, in type C GABA cells of the arcuate nucleus (Burdakov *et al.*, 2003), the membrane depolarization produced by orexin is mediated by a current that reverses near -30 mV under control conditions and is strongly reduced both by the NCX antagonist KB-R7943 and by buffering intracellular Ca^{2+} to very low levels with 10 mM BAPTA [1,2-bis(*O*-aminophenoxy)ethane-*N,N,N',N'*-tetraacetic acid], suggesting that elevation of intracellular Ca^{2+} triggers an inward NCX current in these neurons. It was also shown that lowering extracellular Na^+ shifts the reversal potential of this current to more negative values, while lowering extracellular Ca^{2+} shifts the reversal potential to more positive values – changes that at least qualitatively fit expectations for an NCX current (Luo and Rudy, 1994). In contrast, the orexin-mediated depolarization in dorsal raphe neurons appears mainly mediated by NSCCs as it is not blocked by strong buffering of intracellular Ca^{2+} with BAPTA (Liu *et al.*, 2002) or low extracellular Ca^{2+} (Brown *et al.*, 2002; Liu *et al.*, 2002; Kohlmeier *et al.*, 2008), is not effectively blocked by KB-R7943 (Liu *et al.*, 2002; Kohlmeier *et al.*, 2008) or by intracellular (Liu *et al.*, 2002) and extracellular Cs^+ (Kohlmeier *et al.*, 2008), and has a reversal potential – in low extracellular Ca^{2+} – that shifts from near 0 mV in normal extracellular Na^+ to near -50 mV in 26 mM extracellular Na^+ (Brown *et al.*, 2002).

A hallmark orexin action in expression systems is the elevation of intracellular Ca^{2+} . Both OX_1 and OX_2 receptors release Ca^{2+} from intracellular stores and, at lower orexin concentrations, a primary Ca^{2+} influx is evoked (Kukkonen and Leonard, 2013). The effect of orexin on intracellular Ca^{2+} levels has been examined in only a few types of central neurons (van den Pol *et al.*, 1998; 2001; van den Pol, 1999; Uramura *et al.*, 2001; Lambe and Aghajanian, 2003; Kohlmeier *et al.*, 2004; 2008; Muroya *et al.*, 2004; Ishibashi *et al.*, 2005; Tsujino *et al.*, 2005). Interestingly, there are only a few examples where orexin actions may depend on release from intracellular stores (Korotkova *et al.*, 2002; Burdakov *et al.*, 2003; Muroya *et al.*, 2004). In one study, chelation of intracellular Ca^{2+} with BAPTA, but not reduction of extracellular Ca^{2+} , prevented orexin depolarizations (Burdakov *et al.*, 2003), while in another, thapsigargin reduced orexin-mediated firing (Korotkova *et al.*, 2002). In the third study, direct Ca^{2+} measurements showed that part of the orexin-induced Ca^{2+} elevation was prevented by pretreatment with thapsigargin (Muroya *et al.*, 2004), but the noisy responses make firm conclusions difficult. In other neurons, the orexin-mediated Ca^{2+} elevation is mediated by depolarization and the activation of voltage-gated Ca^{2+} channels (VGCCs) (van den Pol *et al.*, 1998; Uramura *et al.*, 2001; Kohlmeier *et al.*, 2004; 2008; Ishibashi *et al.*, 2005) as it was blocked by low-

ering extracellular Ca^{2+} and, in some cases, was shown to require depolarization, was insensitive to store depletion and/or was sensitive to blockers of VGCCs. Orexin also produces an enhancement of Ca^{2+} influx mediated by VGCCs in some neurons (Kohlmeier *et al.*, 2008; see also Kukkonen and Leonard, 2013). Nevertheless, evidence indicates that orexin receptors can activate PKC (see below) in CNS neurons, which likely requires PLC activity and thus may coincide with inositol-1,4,5-trisphosphate (IP_3)-triggered Ca^{2+} release. It is therefore noteworthy that Ca^{2+} imaging studies in central neurons have been limited to somata and proximal dendrites and space-averaged Ca^{2+} signals, as orexin receptor-mediated release of Ca^{2+} from intracellular stores may occur in a very localized manner and/or in neuronal compartments not yet examined such as the dendrites or synaptic terminals. Methods having high spatial resolution, like 2-photon imaging, should be utilized to address these possibilities.

In addition to mediating depolarization, there is emerging evidence that native orexin receptors alter the integrative properties of their target neurons by modulating postsynaptic ion channels and thereby strongly influence how synaptic inputs from other sources get converted into firing. Orexin-A (400 nM), acting through OX_1 receptors and PKC, reduces the H-current (mediated by hyperpolarization-activated, cyclic nucleotide-gated HCN channels) and produces a negative shift in its voltage dependence in layer 5 prefrontal pyramidal neurons (Li *et al.*, 2010). The prevalence of this action remains to be established but it could profoundly alter excitability and synaptic integration, as these channels are strongly expressed in dendrites (Magee, 1999). Orexins have also been reported to slow spike repolarization (Figure 2A) in solitary tract neurons (Yang and Ferguson, 2003; Yang *et al.*, 2003) and reduce the post-spike afterhyperpolarization (AHP; Figure 2B) in noradrenergic locus coeruleus neurons (Horvath *et al.*, 1999; Murai and Akaike, 2005) consistent with inhibition of a repolarizing K^+ current mediated by voltage-dependent K^+ channels or large-conductance Ca^{2+} -activated K^+ channels, which have recently been shown to be inhibited by orexin in smooth muscle (Squecco *et al.*, 2011). Orexins also inhibit the long-lasting slow AHP that builds up following multiple spikes in paraventricular thalamic neurons (Figure 2C) (Zhang *et al.*, 2010). These cells show robust low-threshold Ca^{2+} spiking, which drives rhythmic bursting, in part, via a Ca^{2+} -dependent K^+ current, termed the slow AHP current (I_{sAHP}). This current, along with a Na^+ -dependent K^+ current, produces strong spike-frequency adaptation in these cells when firing is elicited by prolonged depolarizing current pulses. Orexins inhibit both these currents via PKC, thereby enhancing the excitability of these neurons to sustained depolarizing input (Zhang *et al.*, 2009; 2010). I_{sAHP} is found in many neurons and, although multiple channels appear to mediate this current, it is well known to be suppressed by neurotransmitters via GPCRs that couple to G_s and G_q and it may be regulated by phosphatidylinositol-4,5-bisphosphate (PIP_2) (for review, see Andrade *et al.*, 2012).

Recently, we found a functionally opposite action of orexin-A on serotonergic dorsal raphe neurons. These neurons have a large, medium-duration post-spike AHP that contributes to their characteristic pacemaker firing and strong spike-frequency adaptation (Aghajanian and Vandermaelen, 1982), which is almost entirely mediated by

Figure 2

In addition to producing depolarization, orexins also modulate the integrative properties of neurons in the CNS. (A) Orexin-A (ORX-A, 10 nM) slowed action potential repolarization and broadened the spike without altering the magnitude of AHP in nucleus of the solitary tract neurons. The duration of the action potential at both 50% (APD_{50}) and 90% (APD_{90}) recovery was longer following orexin. This was associated with a reduction in non-inactivating voltage-dependent outward currents (not shown). (B) In dissociated locus coeruleus neurons, orexin-A and orexin-B (ORX-B) reduced the magnitude and duration of the AHP. This too was associated with a reduction in a non-inactivating, voltage-dependent outward current (not shown), which may be different from that reduced in (A). Reprinted from Murai and Akaïke (2005), with permission from Elsevier. (C) In paraventricular thalamic neurons, orexins reduce an I_{sAHP} and decrease spike-frequency adaptation. These neurons have a classical I_{sAHP} , which is mediated mainly by a Ca^{2+} -dependent K^+ current and a Na^+ -dependent K^+ current, which is activated with stronger stimuli. I_{sAHP} was strongly reduced by orexin-A (200 nM; C_1) and by stimulating either the PKA and PKC pathways (not shown). The orexin-A-mediated reduction was blocked by an inhibitor of PKC but not an inhibitor of PKA (C_2). The reduction of this current by orexins (and PKA and PKC activators) decreases spike-frequency adaptation and increases the number of spikes fired for the same input current in these cells (C_3). (D) Orexin-A (300 nM) depolarizes serotonergic dorsal raphe neurons and also enhances a late AHP. Orexin-A (300 nM) produced a suprathreshold depolarization (D_1). The late AHP was evoked (5 spikes at 20 Hz) before orexin application (left arrow) and during orexin (right arrow) after returning to the same baseline membrane potential by current injection (-dc). Orexin made the late AHP larger ($198 \pm 19\%$ of control, $n = 20$) and longer ($429 \pm 52\%$ of control half recovery time, $n = 20$). This orexin-enhanced AHP slowed steady-state firing in response to 100 pA (2 s) injected current pulses (D_2) without changing the shape of the action potential (spikes superimposed from before and after orexin; D_2 inset). Subfigures (A), (B) and (C) are adapted from Yang and Ferguson (2003), Murai and Akaïke (2005), Zhang *et al.* (2010) and are reproduced with permission. Subfigure (D) was adapted from Ishibashi M, Gumenchuk I, Leonard CS (unpubl. data).

small-conductance Ca^{2+} -activated K^+ channels (see Rouchet *et al.*, 2008). Orexin-A enhances this K^+ current and induces a longer-lasting, unidentified Ca^{2+} -dependent late AHP current that appears distinct from I_{sAHP} . Together, these orexin-

enhanced outward currents increase spike-frequency adaptation by slowing down steady-state firing and producing a delayed decrease in excitability (Ishibashi *et al.*, 2012). Collectively, and in contrast to a simple depolarizing action, these

modulatory actions imply that orexin receptor activation can finely tune how target neurons will respond to other inputs. Future studies aimed at understanding the mechanisms, prevalence and impact of this emerging class of actions could provide important insights into how orexins normally regulate information processing in the brain and how this is perturbed in the absence of orexins in narcolepsy.

In addition to postsynaptic actions, orexins have been recognized since the earliest studies in hypothalamic cultures to release neurotransmitters independently of tetrodotoxin-sensitive impulses (van den Pol *et al.*, 1998), suggesting that orexin receptors are located at, or near, presynaptic terminals of some glutamate- and GABA-releasing neurons. This ability to release glutamate and/or GABA by increasing miniature postsynaptic current frequency has been observed in the CNS (van den Pol *et al.*, 1998; Li *et al.*, 2002; Smith *et al.*, 2002; Davis *et al.*, 2003; Acuna-Goycolea and van den Pol, 2009), although the underlying signalling mechanisms have not been explored. In some structures, orexin preferentially releases GABA (Davis *et al.*, 2003) or glutamate (Smith *et al.*, 2002; Acuna-Goycolea and van den Pol, 2009), typically in conjunction with postsynaptic actions. Presumably, this allows the orexins to amplify or attenuate information transmission arising from particular afferents.

Another mechanism by which orexins can influence the release of neurotransmitter from presynaptic terminals is by retrograde paracrine signalling via the endocannabinoid 2-AG (2-arachidonoylglycerol) (see *Orexins and endocannabinoids* in Kukkonen and Leonard, 2013). This has so far been investigated in only a few nuclei: postsynaptic orexin action is supposed to lead to production of 2-AG, which upon exit to the synaptic space stimulates presynaptic CB₁ receptors, leading to a decrease in transmitter release, glutamate in the dorsal raphe nucleus (Haj-Dahmane and Shen, 2005) and GABA in the ventrolateral periaqueductal grey matter (Ho *et al.*, 2011). The mechanism of stimulation of production of 2-AG and its substrate DAG is not clear, but if it is related to the ability of orexin receptors to activate PLC and/or induce Ca²⁺ influx, as expected (see *Orexins and endocannabinoids* in Kukkonen and Leonard, 2013), then the same mechanism is likely operational at other central orexin targets too.

In addition to dynamically adjusting the pre- and postsynaptic properties of their targets, orexins also regulate synaptic plasticity in the hippocampus (Selbach *et al.*, 2004; 2010) and ventral tegmental area (for review, see Baimel and Borgland, 2012). Remarkably, in the ventral tegmental area, this plasticity is critical to behavioural sensitization resulting from cocaine administration (Borgland *et al.*, 2006) and involves an initial but transient increase in the number of postsynaptic NMDA-type glutamate receptors. While it is yet unclear whether regulation of NMDA (or AMPA receptors; Shin *et al.*, 2009) is a prevalent orexin function, it has recently been shown that orexins potentiate the NMDA receptor-driven release of noradrenaline from the somata and dendrites of locus coeruleus neurons (Chen *et al.*, 2008b). These effects on NMDA receptors were sensitive to OX₁ and PKC inhibitors (Borgland *et al.*, 2006; Chen *et al.*, 2008b), which hints at involvement of the PLC–PKC pathway. In the VTA, a similar potentiation of NMDA receptor-mediated synaptic currents was produced by orexin-B in the presence of the OX₁ antagonist SB-334867 (Borgland *et al.*, 2008). This

effect was sensitive to the OX₂ antagonist JNJ-10397049 and PKC inhibitors, suggesting that both OX₁ and OX₂ induce this type of regulation by a common signalling pathway. It will be important to determine if glutamate receptors are regulated by orexins in other neurons.

Do orexin receptor subtypes show effector preferences in the CNS?

The tools available to identify which receptor underlies orexin action on central neurons are quite limited. Expression analysis, which could exclude the presence of one subtype, is hampered by receptor antibodies that are unreliable (Kukkonen, 2012; 2013). Hence, assessment of receptor mRNA and pharmacological analysis utilizing concentration–response relations and receptor subtype-selective antagonists have mainly been used. For orexin agonists, it is generally believed – based on the originally reported affinities and potencies (Sakurai *et al.*, 1998) – that an equal potency of orexin-A and orexin-B indicates OX₂, while a 10-fold greater potency of orexin-A indicates OX₁. The synthetic ligand [Ala11, D-Leu15]-orexin-B, has been reported to be OX₂-selective. However, agonist potency profiles alone are unreliable due to possible *biased agonism/agonist trafficking of receptor responses* or other processes (discussed in Kenakin, 1997; 2011; Kukkonen, 2012). Such issues have been identified for orexin-A, orexin-B and [Ala11, D-Leu15]-orexin-B (Putula *et al.*, 2011), and therefore, agonist-based determinations of orexin receptor subtypes without additional supporting evidence should be considered provisional. In a few cases, receptor knockout mice have also been used to assess whether one or the other receptor is necessary to mediate an orexin action (see below), but this approach is also not without potential problems (Routtenberg, 1996). The use of orexin receptor subtype-selective antagonists requires a pharmacological analysis to show that inhibition occurs with the expected potency, since the available antagonists are not absolutely selective. In the best case, selective antagonists for both subtypes would be used.

Based on the results from expression systems and receptor sequence analysis, there is no reason that both receptors would not be able to couple to any of the effector families described (Kukkonen and Leonard, 2013), although this issue has not been thoroughly studied. The evidence indicates that both native orexin receptors in the CNS inhibit K⁺ currents and activate NSCCs. For example, OX₂ receptor expression is enriched in layer 6 of the neocortex in rat (Trivedi *et al.*, 1998; Marcus *et al.*, 2001). Layer 6b neocortical neurons are depolarized by reduction of a resting K⁺ current and show equivalent responses to 30 nM orexin-A and orexin-B, consistent with OX₂ receptors mediating this action (Bayer *et al.*, 2004). In contrast, rat layer 2/3 prefrontal cortex primarily expresses OX₁ mRNA (Trivedi *et al.*, 1998; Marcus *et al.*, 2001). These pyramidal neurons are depolarized by both reduction of a resting K⁺ current and activation of an NSCC, and the entire response to 400 nM orexin-A is blocked by 1 µM of the OX₁ antagonist SB-334867 while no response is triggered by the 'selective' OX₂ agonist [Ala11, D-Leu15]-orexin-B (Yan *et al.*, 2012), consistent with OX₁ receptors reducing a resting K⁺ current.

Similarly in rat dorsal raphe nucleus, mRNA for both orexin receptors are co-distributed (Trivedi *et al.*, 1998;

Marcus *et al.*, 2001) and can be recovered from the same cells (Brown *et al.*, 2002). Orexin-A and orexin-B activate a NSCC with a similar potency in rat (Brown *et al.*, 2002; Liu *et al.*, 2002; Soffin *et al.*, 2004) but recordings from slices made from OX₁ and OX₂ knockout mice indicate that either receptor is sufficient to mediate the NSCC current (Leonard *et al.*, 2011).

In contrast, reports of NCX activation by orexin are associated with responses thought to be mediated by OX₂ receptors (Eriksson *et al.*, 2001; Wu *et al.*, 2002; 2004; Burdakov *et al.*, 2003). For example, in the tuberomammillary nucleus, NCX is reported to drive the orexin-mediated depolarization and this appears entirely mediated by OX₂ as only OX₂ mRNA is detected by *in situ* hybridization in rat (Marcus *et al.*, 2001), orexin-evoked Ca²⁺ transients are absent in the OX₂ knockout mice (Willie *et al.*, 2003), and orexin-stimulated firing can be rescued by re-expressing OX₂ in tuberomammillary nucleus neurons of conditional OX₂ knockout mice (Mochizuki *et al.*, 2011). In the lateral vestibular nucleus, the orexin-mediated depolarization is suggested to be mediated by both the closure of K⁺ channels and the activation of NCX (Zhang *et al.*, 2011). The depolarization appeared partly mediated by either orexin receptor subtype, although it was not resolved whether OX₂ activation was necessary for the NCX component of the depolarization. Future studies aimed at identifying both the receptors and evoked currents at the molecular level (see *Orexin receptor actions in the CNS*) will be needed to determine if the correlation of OX₂ and NCX is of functional importance, and if so, how it might be mediated.

Finally, while it is likely that orexins mediate the same major physiological responses in the CNS of different species, the expression of individual receptor subtypes may vary between species, and thus the use of techniques with resolving power for the function of receptor subtypes (e.g. subtype-selective antagonists) is required. Moreover, mouse shows alternative splicing of the OX₂ gene with two functional receptor proteins as a result (Chen and Randeva, 2004; Chen *et al.*, 2006), which may complicate the analysis.

Molecular signalling mechanisms in the CNS

Much less is known about the signalling cascades engaged by orexin receptors in the brain than in expression systems. Direct studies suggest orexin receptors couple to (at least) G_{i/o} proteins in rat brain stem and to G_{i/o}, G_s and G_q in rat hypothalamus (see Kukkonen and Leonard, 2013 for details). Other evidence is indirect. A number of studies have implicated the PLC–PKC pathway based on the effectiveness of PKC inhibitors in blocking the orexin-mediated depolarization (Yang *et al.*, 2003; Muroya *et al.*, 2004; Xia *et al.*, 2005), elevation of intracellular Ca²⁺ (Uramura *et al.*, 2001; Kohlmeier *et al.*, 2004; 2008; Muroya *et al.*, 2004), inhibition of the sAHP current (Zhang *et al.*, 2010), enhancement of NMDA receptor currents (Borgland *et al.*, 2006; Chen *et al.*, 2008b) and suppression of H-current (Li *et al.*, 2010); in addition, sensitivity to the PLC inhibitor U73122 is found in some studies (Muroya *et al.*, 2004; Borgland *et al.*, 2006). However, it has also been reported that the orexin-mediated depolarization of dorsal raphe neurons, which is mainly mediated by a NSCC, was not blocked by inhibitors of PKC, PKA or the ERK cascade (Brown *et al.*, 2002). In these same neurons, a PKC inhibitor blocked

the orexin-enhanced Ca²⁺ transients, but the orexin-mediated activation of the NSCC current was still detectable in some of the same neurons, even though fewer neurons showed this response (Kohlmeier *et al.*, 2008), suggesting the presence of PKC-dependent and PKC-independent processes. Yet, in other neurons, the orexin-mediated depolarizations are blocked by inhibitors of PKA, but not PKC (Korotkova *et al.*, 2002; van den Top *et al.*, 2003; Nakamura *et al.*, 2010). Analyses of the signal coupling are hampered by multiple signalling mechanisms of these receptors and possibly even multiple similar channel types in the selected cell population or even in single cells, together with the shortage of good tools (Kukkonen and Leonard, 2013). The situation is further complicated by potential signalling pathway cross-coupling and convergence onto common effectors. For example, somatostatin and met-enkephalin activate inward rectifier K⁺ 3.1/3.2 (Kir3.1/3.2, a.k.a. GIRK) channels in rat locus coeruleus neurons via pertussis toxin-sensitive G-proteins, while substance P suppresses the induced activity of these channels via a pertussis toxin-insensitive mechanism (Velimirovic *et al.*, 1995). Orexin is able to both induce the rapid activity and inhibit the sustained activity of the channels via pertussis toxin-sensitive and -insensitive mechanisms respectively (Hoang *et al.*, 2003).

Thus, in the CNS, there is evidence that orexin receptors couple to multiple effectors including those leading to Ca²⁺ and Na⁺ influx – for which, in most cases, we do not know the channel type or activation mechanism. Moreover, it is evident that that in some central neurons, PLC–PKC and AC–PKA pathways are engaged as has been elaborated in expression systems and other tissues. Given the relative paucity of orexin receptor signalling studies in the CNS, it is plausible that the diverse signalling pathways described in other systems may also be found in the CNS as these studies develop.

How these signalling pathways function in the CNS may depend on the nature of the orexin signals to be detected. Orexins may operate as paracrine signals that act over substantial diffusion distances at very low concentrations or they may operate as more localized synaptic signals at high concentrations. Evidence for the former mode is suggested by the accumulation of orexin in the cerebrospinal fluid over the entire active periods (Zeitzer *et al.*, 2004) and the ability of either intracerebroventricular orexin delivery or ectopic re-expression of the pre-propeptide to rescue orexin-deficient genetic models (Mieda *et al.*, 2004; Liu *et al.*, 2011). Evidence for the latter is suggested by the ability to record orexin-mediated synaptic potentials following electrical stimulation (Yamuy *et al.*, 2004) and rapid arousal responses following optogenetic *in vivo* stimulation (Adamantidis *et al.*, 2007) of orexin neurons.

Orexin receptor modulation of central circuits

Orexin receptor signalling influences multiple homeostatic systems, including those regulating arousal, appetite, metabolism, reward, stress and autonomic function (for review, see Carter *et al.*, 2009; Sharf *et al.*, 2010; Girault *et al.*, 2012; Nattie and Li, 2012). Perhaps most strikingly, orexin signalling is essential for the normal regulation of sleep and waking as its disruption results in narcolepsy with cataplexy – a sleep disorder characterized by excessive sleepiness, sleep attacks, sudden loss of postural muscle tone in response to

strong emotions (cataplexy), and state instability and fragmentation produced by shorter and more frequent bouts of waking and sleep (for review, see Siegel and Boehmer, 2006). Overall, the circuits controlling these systems are not known precisely and undoubtedly involve overlapping populations of neurons in many cases (for review, see Brown *et al.*, 2012). Thus, our understanding of the role played by orexin receptor signalling at particular nodes in these circuits is currently quite incomplete.

In the control of arousal and behavioural state, orexin actions have been identified at many cell groups thought to be important for maintaining arousal including the orexin neurons themselves (Yamanaka *et al.*, 2010) and all tested ascending cholinergic systems (Eggermann *et al.*, 2001; Burlet *et al.*, 2002; Wu *et al.*, 2002; 2004; Hoang *et al.*, 2004; Kohlmeier *et al.*, 2004; 2008; Arrigoni *et al.*, 2010; Leonard *et al.*, 2011) and monoaminergic systems (Hagan *et al.*, 1999; Horvath *et al.*, 1999; Ivanov and Aston-Jones, 2000; Nakamura *et al.*, 2000; Bayer *et al.*, 2001; Brown *et al.*, 2001; 2002; Eriksson *et al.*, 2001; Uramura *et al.*, 2001; Liu *et al.*, 2002; van den Pol *et al.*, 2002; Yamanaka *et al.*, 2002; Hoang *et al.*, 2003; Willie *et al.*, 2003; Kohlmeier *et al.*, 2004; 2008; Korotkova *et al.*, 2003; Soffin *et al.*, 2004; Haj-Dahmane and Shen, 2005; Murai and Akaike, 2005; Borgland *et al.*, 2006; Leonard *et al.*, 2011; Mochizuki *et al.*, 2011; Ishibashi *et al.*, 2012) which form part of the ascending reticular activating system and project to the thalamus and/or cortex (for review, see Jones, 2005). Moreover, orexins excite neurons in the sublaterodorsal region (Brown *et al.*, 2006; 2008), which is an area containing neurons with multiple transmitter phenotypes, and recently recognized as critical in regulating rapid eye movement sleep expression and muscle tone during sleep (Boissard *et al.*, 2002; Lu *et al.*, 2006). At the level of thalamocortical systems, orexin actions appear highly suited to promote arousal and suppress sleep because orexins excite midline, intralaminar and reticular thalamic nuclei, which are part of the 'non-specific' projection system, without exciting 'specific' thalamocortical neurons (Bayer *et al.*, 2002; Govindaiah and Cox, 2006). Except for prefrontal cortex, orexin actions in the neocortex appear restricted to deep layer (6b) neurons, which make intracortical connections to layer 1 where they can interact with midline and intralaminar thalamic inputs (Bayer *et al.*, 2004). Thus, orexins can promote neocortical arousal through both non-specific thalamocortical pathways and the numerous pre-cortical afferent systems that are directly activated by orexins.

Consistent with the idea that thalamocortical actions of orexin are critical for waking, orexin action at these sites appears mediated mainly by OX₂ receptors (Bayer *et al.*, 2002; 2004). OX₂ receptors are particularly important for normal waking as the defect in canine narcolepsy is a null OX₂ receptor (Lin *et al.*, 1999) and mice lacking OX₂ receptors have a narcolepsy phenotype with shorter wake bouts and sleep attacks (Willie *et al.*, 2003), unlike OX₁ null mice that do not have a narcolepsy phenotype (Mieda, 2012). Moreover, in the absence of OX₂, the ability of intracerebroventricularly infused orexin to promote arousal and suppress sleep through OX₁ receptors is impaired (Mieda, 2012). However, recent findings utilizing a conditional OX₂ receptor knockout mouse indicate that re-expression of OX₂ in the tuberal region of the hypothalamus, including the histaminergic tuberomammil-

lary nucleus, is sufficient to reinstate normal wake bout durations although fragmentation of sleep was not rescued (Mochizuki *et al.*, 2011). This indicates, however, that thalamocortical orexin actions are not necessary for maintaining normal wake bouts. Given the apparent redundancies in arousal systems, orexin actions in thalamocortical systems may still be sufficient to stabilize normal wake bouts and/or it may be required for other aspects of waking (e.g. vigilance) yet to be determined.

Beyond the control of arousal and behavioural state, orexins influence numerous other systems as noted earlier. Several lines of evidence indicate orexins act on the neural substrates regulating motivated behaviour and reward. For example, OX₁ receptors depolarize ventral tegmental area GABA and dopamine neurons (Nakamura *et al.*, 2000; Uramura *et al.*, 2001; Korotkova *et al.*, 2003), and actions of orexin here appear necessary for behavioural sensitization to cocaine administration by up-regulating synaptic NMDA receptors (see above). Orexins depolarize neurons in many of the structures that are efferent targets of the ventral tegmental area system including neurons in the shell region of the nucleus accumbens via OX₂ (Mukai *et al.*, 2009), the bed nucleus of the stria terminalis (Lungwitz *et al.*, 2012) and neurons that provide input to the nucleus accumbens, including the central nucleus of the amygdala via OX₂ receptors (Bisetti *et al.*, 2006), paraventricular thalamic nucleus (Ishibashi *et al.*, 2005; Huang *et al.*, 2006; Kolaj *et al.*, 2007; Doroshenko and Renaud, 2009; Zhang *et al.*, 2009; 2010) and prefrontal cortex (Li *et al.*, 2010; Yan *et al.*, 2012). Orexins also depolarize neurons in structures that provide afferent input to the ventral tegmental area including laterodorsal tegmentum (Burlet *et al.*, 2002; Kohlmeier *et al.*, 2004; 2008; Leonard *et al.*, 2011; Ishibashi *et al.*, 2012; Takahashi *et al.*, 2002) and pedunculopontine tegmentum (Kim *et al.*, 2009a; 2009b) via OX₁ receptors.

Orexins stimulate feeding (Sakurai *et al.*, 1998) and orexin neurons respond to signals of metabolic status (Yamanaka *et al.*, 2003; Burdakov *et al.*, 2006; Karnani *et al.*, 2011). They provide strong output to the arcuate nucleus where they excite orexigenic neuropeptide Y/agouti-related protein (NPY/AgRP) neurons and produce rhythmic bursting (van den Top *et al.*, 2004) via OX₂ receptors and activation of NCX, likely stimulated by Ca²⁺ release from intracellular stores (Burdakov *et al.*, 2003; Muroya *et al.*, 2004). Orexins also can excite the anorexigenic preproopiomelanocortin (POMC) arcuate neurons, many of which project into the median eminence, by apparent activation of NCX (Acuna-Goycolea and van den Pol, 2009). This result contradicts a previous study that concluded orexins indirectly decrease firing in POMC arcuate neurons by suppressing spontaneous excitatory and increasing spontaneous inhibitory synaptic currents (Ma *et al.*, 2007). As noted by the authors, the orexin-mediated depolarization reversed near -40 mV and in the prior study, orexin actions were studied at depolarized membrane potentials suggesting that the depolarizing action might have been missed. While future studies should resolve the basis for these differences, these studies serve to remind us that the pathways and effectors engaged by orexin receptors may well be sensitive to the internal state of the cell, yielding different actions under different conditions. NCX might serve such a purpose as its activity is tied to metabolic

factors as well as signalling pathways (DiPolo and Beauge, 2006; Török, 2007).

Orexins strongly activate the autonomic nervous system and regulate visceral sensory-motor control (Hwang *et al.*, 2001; Follwell and Ferguson, 2002; Smith *et al.*, 2002; Yang and Ferguson, 2002; 2003; Davis *et al.*, 2003; Grabauskas and Moises, 2003; van den Top *et al.*, 2003; Yang *et al.*, 2003; Dergacheva *et al.*, 2005; 2012; Huang *et al.*, 2010). Finally, orexins also can influence the somatic sensory-motor systems, including superficial dorsal horn neurons of the spinal cord (van den Pol, 1999; Grudt *et al.*, 2002) and ventrolateral periaqueductal grey neurons (Ho *et al.*, 2011), both of which regulate pain transmission, and descending vestibulospinal neurons, which can powerfully influence posture and motor performance (Zhang *et al.*, 2011).

In conclusion, native orexin receptors throughout the CNS drive membrane depolarization, increase intracellular Ca^{2+} and increase transmitter release from presynaptic terminals. Emerging evidence indicates that these receptors also strongly modulate cell excitability through multiple means and can regulate synaptic plasticity. Multiple effectors and signalling mechanisms are involved but our limited knowledge mostly precludes molecular identification of the signalling pathways and effectors mediating these actions. Future approaches should make use of the recently developed pharmacological tools to inhibit signal cascades [e.g. (phospho)lipases and kinases] and orexin receptor subtypes. In addition, better resolution of the membrane currents regulated by orexins is necessary for their identification. This will require better electrophysiological isolation to enable their study over wider range of voltages, more extensive ion substitution experiments, development and use of better pharmacological blockers and ultimately utilization of knockout or knockdown approaches.

Orexin responses outside the CNS

Gastrointestinal tract

OX_1 and OX_2 mRNA was detected in rat and guinea pig myenteric plexi (Kirchgessner and Liu, 1999). Orexin-A (30 nM) excited guinea pig ileal submucosal neurons, and an increase in input resistance was seen. After hyperpolarization was also reduced. Both responses suggest inhibition of K^+ channels (Kirchgessner and Liu, 1999). However, orexin-A also reduced the amplitude of the evoked excitatory postsynaptic potentials. No synaptic/action potential block was applied in these studies. In another study, orexin-A depolarized guinea pig ileal myenteric neurons; reduced input resistance, current reversal around the equilibrium potential of K^+ and resistance to synaptic block suggest postsynaptic inhibition of K^+ channels (Katayama *et al.*, 2003). Orexin also enhanced evoked cholinergic potentials but did not affect direct acetylcholine responses, suggesting presynaptic facilitation. Acetylcholine overflow and contraction was seen in an orexin-A-stimulated guinea pig ileal preparation; results with tetrodotoxin, atropine and SB-334867 suggest that orexin-A acts on neuronal OX_1 receptors increasing acetylcholine overflow, which depolarizes the muscle via muscarinic receptors (Matsuo *et al.*, 2002).

Mouse duodenum was also contracted by orexin-A (300 nM) (Squecco *et al.*, 2011). The contraction was partially inhibited by the L-type VGCC blocker nifedipine (1 μM), nearly fully by 10 μM 2-aminoethoxydiphenyl borate [inhibitor of IP_3 receptors, *orai1* and some transient receptor potential (TRP) channels] and fully by 50 μM Ni^{2+} and 1 mM tetraethylammonium chloride. Multiple channels were affected by orexin-A: activity of voltage-gated Na^+ channels as well as VGCCs of T- and L-type was enhanced while BK-type K^+ channels were inhibited. In addition, activation of receptor- and store-operated Ca^{2+} channels was suggested (Squecco *et al.*, 2011). The results demonstrate the problems orexin researchers are facing from the multiple signal pathways utilized by orexin receptors and the limitations of the pharmacological inhibitors.

STC-1 mouse gastric endocrine carcinoid tumour cells, apparently isolated from genetically oncogene-harboring mice, express mRNA for both OX_1 and OX_2 receptors (Larsson *et al.*, 2003). Orexin-A potently stimulated cholecystokinin secretion from these cells, putatively by inducing depolarization and activation of L-type VGCCs. No obvious Ca^{2+} or cAMP response to orexin-A was seen, but the former may be hidden under the strong spontaneous Ca^{2+} oscillations.

OX_1 receptors have been suggested to be expressed in primary human colorectal tumours and also in many cell lines established from primary tumours but not in the normal colon epithelium (Voisin *et al.*, 2011; see *Cell lines natively expressing orexin receptors* below and *Cell death* in Kukkonen and Leonard, 2013).

Pituitary gland

It is somewhat unclear which parts of the pituitary express which orexin receptors in which species (see Kukkonen, 2013). In rat corticotropes, orexin-A inhibits adrenocorticotropin release in response to corticotropin-releasing hormone (Samson and Taylor, 2001). An inhibitor of PKC blocks the orexin response, while pertussis toxin does not; the target of PKC is unknown. In isolated sheep somatotropes, orexin-A, instead, enhances L-type VGCC current in a PKC-dependent manner and augments growth hormone release (Chen and Xu, 2003). Whether the latter is mediated by the PKC pathway was not assessed.

Adrenal gland

Orexin receptor activation of G-proteins has been investigated by Randeva and co-workers in adrenal cortex utilizing the GTP-azidoanilide labelling methods (see *Orexin receptor coupling partners: heterotrimeric G-proteins* in Kukkonen and Leonard, 2013). In human and rat cells, coupling to G_s , G_i and G_q is seen (Karteris *et al.*, 2001; 2005; Randeva *et al.*, 2001). Whether mainly OX_1 or OX_2 receptors are expressed in man is unsettled (Karteris *et al.*, 2001; Randeva *et al.*, 2001; Mazzocchi *et al.*, 2001b), while rat has been reported to express mRNA for both OX_1 and OX_2 (Karteris *et al.*, 2005). Both human and rat cells respond to orexin by increasing glucocorticoid (cortisol and corticosterone, respectively) synthesis/release via the AC-PKA pathway (Malendowicz *et al.*, 1999; Mazzocchi *et al.*, 2001b). This could be mediated by G_s , but this has not been verified, and PLC is also activated by orexins in these cells (Randeva *et al.*, 2001; Karteris *et al.*, 2005).

H295R human adrenocortical carcinoma cells express both OX₁ and OX₂ receptor mRNA, although OX₂ is more highly expressed (Ramanjaneya *et al.*, 2008; Wenzel *et al.*, 2009). Orexin receptor activation stimulates cortisol release and expression of proteins involved in steroidogenesis like steroidogenic acute regulatory protein (StAR; mRNA and protein), different cytochrome P450 (CYP) species (mRNA) and 3 β -hydroxysteroid dehydrogenase (HSD3B2; mRNA) (Ramanjaneya *et al.*, 2008; Wenzel *et al.*, 2009). Ca²⁺ is elevated at high orexin concentrations, but the MAPKs, ERK and p38 are phosphorylated in the low nanomolar range (Ramanjaneya *et al.*, 2009; Wenzel *et al.*, 2009). PKC phosphorylation is responsible for the ERK activation, and inhibition of either one inhibits most of the HSD3B2 mRNA induction (Ramanjaneya *et al.*, 2009; Wenzel *et al.*, 2009). The results are complicated and partly contradictory, and it remains unclear whether ERK activation is responsible for all the steroidogenic actions (only HSD3B2 mRNA induction was assessed). The result concerning the PKC–ERK cascade would appear contradictory to the results with the primary adrenal cortical cells. This could be explained by a distorted cancer phenotype of the cell line; however, it is also conceivable that the PKC–ERK response seen in H295R cells relates to cell differentiation rather than regular stimulation of steroid biosynthesis.

Many studies find no response to orexins with respect to aldosterone or catecholamine release, but recently, amperometric recordings showed catecholamine release via OX₁ receptors in cultured rat chromaffin cells (Chen *et al.*, 2008a). Primary human pheochromocytomas (OX₂ mRNA) also release catecholamines upon orexin stimulation (Mazzocchi *et al.*, 2001a). PLC, but not AC, is stimulated in these cells, and catecholamine release is suggested to be mediated by the PLC–PKC pathway. Aldosterone release from cultured porcine chromaffin cells is stimulated only at high orexin concentrations (Nanmoku *et al.*, 2002). The signal pathways are unclear.

Endocrine and exocrine pancreas

Whether (exogenous) orexinergic stimulation is capable of regulating release of pancreatic glucagon and insulin or other processes in endocrine pancreas is under debate. Some reports show expression of orexin receptor mRNA in endocrine pancreas and even responses in isolated tissue fragment, but the signal cascades have not been analysed. InR1-G9 cells are glucagon-secreting cells subcloned from Syrian golden hamster insulinoma cells. It is unclear, which orexin receptors subtype these cells express (as this was only determined by antibodies), but the cells functionally responded to orexin-A in nanomolar range by phosphorylation of phosphoinositide-dependent kinase 1 (PDK1) and PKB, which suggests activation of the PI3K pathway (Göncz *et al.*, 2008). Orexin-A stimulated phosphorylation of the PKB-target protein, transcription factor Forkhead box protein O1 (FOXO1), and inhibition of PI3K or knockdown of FOXO1 reversed orexin-A-mediated decrease of proglucagon mRNA (Göncz *et al.*, 2008). GPCRs are known to utilize several pathways for activation of class Ia and class Ib PI3Ks; it is thus far unclear how orexin receptors do it in these cells. There are a few other indications of PI3K activation by orexin receptors (Ammoun *et al.*, 2006a; *White and brown adipose tissue*). In the

paper (Göncz *et al.*, 2008), the authors use rat insulinoma Ins-1 cells as a positive control for OX₁ receptors; however, there are no published reports indicating the presence of OX₁ receptors in Ins-1 cells.

There are no reports of orexin signalling in the exocrine pancreas except for the rat pancreatic acinar tumour AR42J cells, which express OX₂ receptors. Orexins rather weakly stimulated Ca²⁺ mobilization in these cells but with high potency (subnanomolar) (Harris *et al.*, 2002). Amylase secretion was stimulated 100-fold less potently (Harris *et al.*, 2002) and cell death, in the long run, by a further 10-fold lower potency (Voisin *et al.*, 2006). Causal relationships between these responses have, unfortunately, not been determined.

Male reproductive system

OX₁ and OX₂ receptor mRNA has been detected in different sites in the male reproductive tract of man and rat (Jöhren *et al.*, 2001; Barreiro *et al.*, 2004; Karteris *et al.*, 2004). Orexin-A (possibly via OX₁ receptors) stimulates testosterone production and decreases mRNA for anti-Müllerian hormone in rat testis via unknown pathways (Barreiro *et al.*, 2004; 2005). In human male testicular membranes, orexin-A stimulates PLC (Karteris *et al.*, 2004).

White and brown adipose tissue

Human primary white adipocytes of subcutaneous and omental adipose tissue express mRNA for both OX₁ and OX₂ receptors (Digby *et al.*, 2006). Orexin responses (orexin-A and orexin-B, 100 nM) were investigated. In subcutaneous fat, PPAR γ 2 mRNA was increased, while in omental fat, hormone-sensitive lipase mRNA was decreased (Digby *et al.*, 2006). In differentiated mouse white adipocyte-like 3T3-L1 cells (OX₁ and OX₂ mRNA), orexin-A stimulated PI3K and, in PI3K-dependent manner, glucose uptake and triglyceride synthesis (Skrzypski *et al.*, 2011). Orexin-A stimulated ERK phosphorylation, increased PPAR γ 2 mRNA and stimulated adiponectin release, while siRNA against PPAR γ (γ 2?) blocked orexin-A-induced increase in triglyceride content and adiponectin release. In contrast, baseline lipolysis was inhibited. Orexin-A has been reported to stimulate proliferation (but not differentiation) of undifferentiated 3T3-L1 cells (and also of another fibroblast cell line, NIH3T3); however, the concentration–response relationship and the response magnitude is very different in the two studies (Zwirski-Korczala *et al.*, 2007; Skrzypski *et al.*, 2012). Orexin-A also activated ERK but not PKB (Skrzypski *et al.*, 2012). This appears contradictory to the finding that PI3K would be stimulated in differentiated cells; however, the authors have not assessed the PKB in undifferentiated cells or phosphatidylinositol-3,4,5-trisphosphate in differentiated cells. ERK activity was suggested to be protective against cell death by serum starvation as the protective effect of orexin-A was blocked by MAPK/ERK kinase 1 (MEK1) inhibition. Glucose uptake and PPAR γ 2 expression was increased in rat primary pre-adipocytes by orexin-A, but differentiation to adipocytes was not stimulated (Skrzypski *et al.*, 2011; 2012).

Placentally produced orexins were recently identified as pivotally contributing to the prenatal development of brown adipose tissue in mice (Sellayah *et al.*, 2011). Orexin-A, via OX₁ receptors, triggered the differentiation programme in

mouse primary preadipocytes and mouse embryonic fibroblasts (MEFs), C3H10T1/2 mouse mesenchymal stem cells and HIB1b mouse preadipocytes; differentiation was evaluated by morphological and mRNA markers. The signal pathways inducing differentiation are unclear because signal transduction was mainly assessed in already differentiated C3H10T1/2 cells. In these cells and in mouse primary brown pre-adipocytes, orexin stimulation activated p38 and the transcription factor SMAD1/5. Upon more detailed investigations in C3H10T1/2 cells, orexin-A was seen to induce expression of mRNA for both bone morphogenic protein 7 (BMP7) and BMPRI1A receptor during differentiation. The signal cascade, based on pharmacological inhibitors, was suggested to proceed from OX₁ receptors partly via BMP7/BMPRI1A and partly via p38 MAPK. Even BMP7 signalling was suggested to partially require p38 (Sellayah *et al.*, 2011).

Haematopoietic cells

Despite some reports, firm evidence is lacking for the expression of orexin receptors in hematopoietic cells or their precursors. See discussion in Kukkonen (2013).

Cell lines natively expressing orexin receptors

A number of cancer cell lines were identified to express orexin receptor mRNA by RT-PCR. The cell lines expressing OX₁ mRNA include human neuroblastoma SK-N-MC and human colon carcinoma cells HT29-D4, Caco-2, SW480 and LoVo (Rouet-Benzineb *et al.*, 2004) (please note that not all the cell lines have been examined for expression of OX₂). OX₂ receptor mRNA is expressed in rat pancreatic acinar tumour line AR42J (Harris *et al.*, 2002). These cell lines show decreased cell division and enhanced cell death upon orexin exposure (Rouet-Benzineb *et al.*, 2004; Voisin *et al.*, 2006); however, it has not been examined whether the former results from a decrease in proliferation or from the proceeding cell death. There also may be heterogeneity in these cell lines (as in most cell lines); we, for instance, have not been able to measure orexin responses in our SK-N-MC cells (Kukkonen *et al.*, unpubl. data).

H295R human adrenocortical carcinoma cells and pancreatic tumour cells are addressed under the sections *Adrenal gland* and *Endocrine and exocrine pancreas*. Also, some other cell lines have been reported to respond to orexin, but they have found no wider use, or are problematic, for instance, by responding to orexins only at high concentrations.

In summary, many peripheral tissues express orexin receptors and respond (sometimes strongly) to exogenous orexins. However, a major question remaining is whether orexin (or another ligand) can reach these receptors under physiological (or pathological) conditions (see the *Conclusions* section). While this seems to be so for brown adipose tissue, the question remains open for other tissues. For possible orexin system-targeting therapy (see, e.g. *Cell death* in Kukkonen and Leonard, 2013, and the *Conclusions* section), such physiological access would, however, be less significant.

Recombinant cells

Recombinant cell lines have found much use in signalling research for orexin receptors as native orexin receptor-

expressing cells have been difficult to isolate in suitable quantities, and native cell lines are scarce. Recombinant cells allow for genetic and physiological methods of analysis that are difficult to apply to native cells. However, recombinant cell lines are unrelated to, or only distantly related to, native orexin receptor-expressing cells. Therefore, results may be difficult to extrapolate to native situations. Nevertheless, remarkably similar responses have been seen: orexins, for instance, regulate NSCCs in both neurons and recombinant neuronal and non-neuronal cells (see *Orexin receptor actions in the CNS*, and *Ca²⁺ and Depolarization and synaptic functions* in Kukkonen and Leonard, 2013). Heterologous receptor expression platforms are often also criticized for causing artificial signal coupling not present in native cells. While being a justified concern, there is no clear evidence for this with orexin receptors. Moreover, the orexin receptor levels are unknown in native cells, and receptor levels could also be high at postsynaptic regions. Moreover, *human* orexin receptor signalling can be studied in recombinant expression systems in contrast to studies on native cells, which have focused mainly on rodent cells. Thus, it is possible that species-specific differences in signalling and regulation are yet to be discovered.

CHO cells (based on the CHO-K1 clone) are the cells most used for orexin receptor studies. These were also the first stable recombinant cell lines to be produced, probably simultaneously, in several laboratories (Sakurai *et al.*, 1998; Smart *et al.*, 1999; Lund *et al.*, 2000; Ammoun *et al.*, 2003). The human OX₁ receptor has been most extensively investigated; the fact that the same cell lines have been used in a number of studies allows comparison of the potency of activation of different signal cascades, which are summarized in Figure 3. As discussed in Kukkonen and Leonard (2013), multiple signalling cascades are activated in these cells. G-proteins of the families G_q, G_i and G_s are suggested to be activated (Lund *et al.*, 2000; Holmqvist *et al.*, 2005), but there is mainly indirect evidence for this (see *Orexin receptor coupling partners: heterotrimeric G-proteins* in Kukkonen and Leonard, 2013). Downstream, a potent activation of Ca²⁺ influx/inward current and the phospholipases cytosolic phospholipase A₂ (cPLA₂), PLC (hydrolysing phosphoinositides PI and/or PIP) and phospholipase D1 (PLD1) is seen (Lund *et al.*, 2000; Kukkonen and Åkerman, 2001; Larsson *et al.*, 2005; Ammoun *et al.*, 2006a; Johansson *et al.*, 2007; 2008; Turunen *et al.*, 2010; 2012; reviewed in Kukkonen and Leonard, 2013) (Figure 3). Fairly potently activated signal cascades go to ERK, cell death (p38 MAPK) and diacylglycerol lipase (DGL) (via the PLC pathway) (Ammoun *et al.*, 2006a,b; Turunen *et al.*, 2012; reviewed in Kukkonen and Leonard, 2013), while hydrolysis of PIP₂ (and generation of IP₃) and activation of G_s require relatively high orexin concentrations (Holmqvist *et al.*, 2005; Johansson *et al.*, 2008; reviewed in Kukkonen and Leonard, 2013) (Figure 3). We have assessed some of the signal cascades via their downstream effectors, like PLC and/or PLD signalling via DGL activity, translocation of protein kinase C γ -C1 domain to the plasma membrane and the novel PKC (nPKC)-dependent component of AC activation (Figure 3). The signal cascades are dependent on each other, as determined utilizing a pharmacological analysis. The cPLA₂ cascade contributes to the Ca²⁺ influx, nPKC is required for PLD1 activation, both PLD1 and PLC cascades

contribute to the PKC translocation/activation, PLC cascade produces the DAG required for DGL, and IP₃ induces Ca²⁺ release (Ekholm *et al.*, 2007; Johansson *et al.*, 2008; Jäntti *et al.*, 2012; Turunen *et al.*, 2012) (Figure 3). PLC, PLD and cPLA₂ cascades should be linked via PIP₂ as well: PLD should stimulate PIP₂ generation, and PIP₂ is required for PLD activity and it may also enhance cPLA₂ activity (reviewed in Ghosh *et al.*, 2006; Kukkonen, 2011). The ERK cascade can be partially inhibited by inhibiting many signal cascades (Ammoun *et al.*, 2006a). The most perplexing findings relate to Ca²⁺ influx and nPKC. Ca²⁺ influx seems to amplify or gate many of the pathways via an unknown mechanism, but it is also itself regulated by one of these pathways, cPLA₂ (Turunen *et al.*, 2010; 2012; see Ca²⁺ in Kukkonen and Leonard, 2013). Some nPKC (possibly PKCδ) gates PLD1 activation by orexin,

Figure 3

Summary of concentration–response relations for different responses produced by orexin-A at the human OX₁ receptor. This illustrates the different potencies with which orexin-A stimulates different signalling cascades under conditions of equal receptor expression levels in the same clone of CHO cells. Thus, cell background and receptor expression levels are equal across cases so potencies are directly comparable. The results are expressed as % of maximal response for each output. The responses measured are: 'inward current' (whole-cell patch-clamp recordings), 'cPLA₂' (pyrrophenone-sensitive and tetrahydrolipstatin-insensitive AA release chromatographically measured in ¹⁴C-AA-labelled cells), 'Ca²⁺' (cytosolic Ca²⁺ elevation measured with fura-2 parallel to the patch-clamp recordings), 'PLD1' (PLD transphosphatidylase assay in ¹⁴C-oleic acid-labelled cells with chromatographic separation; PLD1 defined by pharmacological PLD1 and PLD2 inhibitors), 'PKCδ (AC)' [nPKC (likely PKCδ)-dependent AC stimulation measured chromatographically in ³H-adenine-labelled cells], 'PKCγ-C1 (transl.; PLD+PLC)' (DAG generation by both PLC and PLD measured by translocation of the fusion protein of C1-domain of PKCγ and green fluorescent protein to the plasma membrane), 'PLC total' (total inositol phosphate release from ³H-inositol-labelled cells determined by chromatography), 'PKCγ-C1 (transl.; PLC)' (DAG generation by PLC alone measured by translocation of the fusion protein of C1-domain of PKCγ and green fluorescent protein to the plasma membrane in cells expressing dominant-negative PLD), 'DGL' (tetrahydrolipstatin-sensitive and pyrrophenone-insensitive 2-AG release chromatographically measured in ¹⁴C-AA-labelled cells), 'cell death' (assessed by staining and counting of viable cells), 'ERK2' [ERK2 phosphorylation assessed by Western blotting against the phosphorylated (active) ERK1/2 species], 'PLC-PIP₂' (IP₃ release assessed by a IP₃-binding protein kit and by translocation of the PH-domain of PLCδ1 from the plasma membrane upon PLC activity towards PIP₂), and 'G_s' (Gα_s-dependent AC stimulation measured chromatographically in ³H-adenine-labelled cells). For the sake of clarity, only curve-fitting results and not the original data points are presented. The curves can be identified with the symbols added on the traces. The measurements originate from the following studies: Holmqvist *et al.* (2005); Larsson *et al.* (2005); Ammoun *et al.* (2006a,b); Johansson *et al.* (2008); Jäntti *et al.* (2012); Turunen *et al.* (2012).

but this seems to be independent of PLC activity (Jäntti *et al.*, 2012). OX₂ signalling cascades have been more seldom assessed. OX₂ receptor stimulation equally well elevates Ca²⁺ and activates ERK in CHO cells (Sakurai *et al.*, 1998; Smart *et al.*, 1999; Ammoun *et al.*, 2003; 2006a; Putula *et al.*, 2011), and also activates PLC (Tang *et al.*, 2008; Kukkonen *et al.*, unpubl. data). Some of the putative relationships of the signal cascades are presented in Figure 4.

CHO-S cells, which represent a suspension-adapted clone of CHO-K1, have been used in the studies of Laburthe and co-workers on cell death (see *Cell death* in Kukkonen and Leonard, 2013). In these cells, OX₁ receptors elevate Ca²⁺, activate PLC and induce cell death (Voisin *et al.*, 2008; El Firar *et al.*, 2009). The authors have also shown that both rat orexin receptor subtypes induce apoptosis of these cells (Voisin *et al.*, 2006).

HEK-293 cells are the next most used cell line. Stable clones, including tetracyclin-inducible ones, have been established in several laboratories (Ellis *et al.*, 2006; Magga *et al.*, 2006; Tang *et al.*, 2008; Ward *et al.*, 2011), and the cells have also been utilized for transient orexin receptor expression.

Figure 4

Schematic summary of some of the relationships of human OX_1 receptor signalling cascades in CHO cells as described in Figure 3. References are as for Figure 3. While G_q may underlie PLC activation (and possibly other responses), this has not been explicitly assessed and is thus not indicated in the figure. L-GPL, lysoglycerophospholipid; PA, phosphatidic acid.

Human OX_1 receptors are known to connect to Ca^{2+} elevation (Maggia *et al.*, 2006). Transient expression has shown the same for human OX_2 receptors, and both receptors couple to PLC as well (Tang *et al.*, 2008; Putula *et al.*, 2011; Putula and Kukkonen, 2012). Ca^{2+} signalling of OX_1 receptors utilizes both influx and release; the mechanisms of the Ca^{2+} influx-dependent oscillations are described under Ca^{2+} in Kukkonen and Leonard (2013). We have seen release of arachidonic acid (AA) and 2-AG from stably and transiently OX_1 -expressing cells upon OX_1 receptor stimulation (Peltonen *et al.*, 2009; Turunen *et al.*, 2012); the origins of these have not been determined, but it is reasonable to assume that at least 2-AG results from PLC activity. Transiently expressed OX_1 receptors have been shown to engage β -arrestin in their signalling to ERK in HEK-293 (see *Orexin receptor coupling partners: interaction with other proteins* in Kukkonen and Leonard, 2013). OX_2 receptors also activate AC and ERK and p38 MAPK cascades; both PKA and PKC are suggested to contribute to the ERK but not to the p38 cascade (Tang *et al.*, 2008).

As an attempt to create a more neuronal model for orexin signalling studies, we established stable human orexin receptor-expressing clones of neuro-2a mouse neuroblastoma and PC12 rat pheochromocytoma cells (Holmqvist *et al.*, 2002). Unfortunately, the cells have remained rather unexplored. The original study showed that both receptor subtypes couple to Ca^{2+} signalling (likely both influx and release as in CHO and HEK-293 cells) and PLC in these cell lines (Holmqvist *et al.*, 2002). Ca^{2+} release was shown to require IP_3 while the receptor-operated Ca^{2+} influx was independent of IP_3 in neuro-2a- OX_1 cells, similar to CHO cells (Ekholm *et al.*, 2007). Also, ERK is activated upon OX_1 receptor stimulation in these cells (Ekholm *et al.*, 2007). In neuro-2a- OX_1 cells, but not in PC12- OX_1 cells, 2-AG and AA release is seen upon

orexin stimulation; the source, like in HEK-293 cells, is undetermined (Turunen *et al.*, 2012).

Stable MEF-h OX_1 cells have been used in studies of cell death to assess the role of $G_{q/11}$ in the response. In these cells, orexin-A (1 μ M) induces cell death and stimulates PLC, but the responses are absent when MEF cells from the $G_{q/11}$ -knockout are used (Voisin *et al.*, 2008).

Also, some other cell lines have been constructed, but they have found no wider use, or show some problems. Transient expression of orexin receptors utilizing liposome-based transfection or transduction with mammalized baculovirus has also been reported in IMR-32, CHO and MEF cells (Näsman *et al.*, 2006; Louhivuori *et al.*, 2010; Jäntti *et al.*, 2013) (and also for HEK-293 cells as described earlier). Differentiated IMR-32 cells show Ca^{2+} transients related to the action of NSCCs and NCX (see Ca^{2+} in Kukkonen and Leonard, 2013). MEF and HEK-293 cells have been utilized for translocation and β -arrestin studies (see *Orexin receptor coupling partners: interaction with other proteins* in Kukkonen and Leonard, 2013). Transiently transfected HEK-293 cells have also been utilized for the investigation of orexin receptor coupling to Kir3.1/3.2 channels; orexin receptors inhibit these channels, which may mimic their action in the CNS (Hoang *et al.*, 2003) (see *Central nervous system and Depolarization and synaptic functions* in Kukkonen and Leonard, 2013).

Conclusions

In these two reviews (the present study and Kukkonen and Leonard, 2013), we have gathered and analysed current knowledge about orexin receptor signalling. It is obvious that orexin receptors possess the ability to signal in multiple ways. The mechanisms that determine which pathway is used in which cell type and situation are unknown. The analysis of signal cascades and target proteins is not easily performed in native cells; this is especially difficult in neurons, and as a consequence, relatively little molecular data are available. Thus, most of the signalling analysis has been performed in recombinant cell lines, mainly CHO cells, and with respect to some specific responses, in certain native cell lines. We believe that the responses seen in recombinant cell lines indeed represent physiological signalling mechanisms of orexin receptors, but where these different pathways are utilized remain mostly obscure as signalling pathways in native cells have been underexplored. The information obtained in cell lines could be utilized to formulate specific tests for native cells especially by utilizing novel pharmacological inhibitors that would be expected to reveal important new information. Thus far, the information flow in this direction seems limited, and traditional, less conclusive approaches with inhibitors having less selective or even doubtful pharmacological profiles (e.g. D609, U73122, KB-R7943) are still often used without adequate controls. However, it must be noted that the pharmacological tools for this type of research are still very limited, which thus calls for even more judicious use. More information is constantly generated and novel tools developed, which will hopefully allow, for instance, distinction of TRP channel isoforms.

One major question relating to orexin receptor signalling is its physiological importance. In CNS neurons, orexin receptors act at all levels of the neuroaxis to effect depolarization. Emerging evidence suggests that orexin receptor action is more subtle than this simple excitation, and that they dynamically adjust presynaptic activity and postsynaptic responsiveness. Orexin receptors also can regulate the expression of synaptic plasticity and potentially the expression of target neuron phenotypes. Nevertheless, linking the action mediated by orexin receptors at particular sites to overall system or circuit functions remains quite challenging, although the use of receptor/peptide deletion models and orexin receptor antagonists has been fruitful in some cases. The major effect of orexin peptide/receptor dysfunction is dysregulation of sleep-arousal behaviours, but other phenotypes, while perhaps less obvious, have (Kayaba *et al.*, 2003) and will be discovered, considering the widespread influence of the peptide-receptor system. Being harder to uncover does not mean they are less important, but that they may involve processes protected by redundancy in regulatory systems or developmental compensation. For the peripheral systems, no clear phenotypes have yet been described, except for the developmental failure of brown adipocytes. While we find orexin receptor mRNA expression and functional responses in many peripheral tissues, preproorexin expression is found at very few sites – preproorexin mRNA expression has been reported in the gastrointestinal tract, testis, adrenal gland, pancreas and kidney (Sakurai *et al.*, 1998; Kirchgessner and Liu, 1999; Jöhren *et al.*, 2001; Nakabayashi *et al.*, 2003; Karteris *et al.*, 2004) – while there are probably no circulating orexins. Would then the peripheral orexin receptors and the responses they show to exogenous orexin stimulation have any physiological functions? One possibility, assuming there is a reason that these receptors are expressed, is that there are natural ligands for these receptors other than preproorexin-derived peptides. Based mainly on a single study (Nakabayashi *et al.*, 2003), it seems that preproorexin expression might be more widespread in peripheral organs of man than rodents; could there be species-specific functions? If the peripheral orexin receptors have physiological significance in man, these may be manifested in side effects of orexin receptor antagonist therapy (Winrow and Renger, 2013).

The orexin system is an obvious therapeutic target for disorders of sleep and wakefulness. Both the native ligands (peptide processing, degradation) and the receptors (agonists, antagonists, allosteric modulation) could be targeted for drug development. Many orexin receptor antagonists (mainly either OX₂-selective or non-selective) are under development or testing (Roecker and Coleman, 2008) and the first one of these dual receptor antagonists, suvorexant (MK-4305), is likely to be released in the US market soon (Winrow and Renger, 2013). Synthetic orexin receptor agonists, in contrast, have not been reported on except for one patent (Yanagisawa, 2010), although they would likely be useful in increasing/stabilizing wakefulness and as a treatment for excessive sleepiness (e.g. in narcolepsy) and for killing cancer cells (*Cell death* in Kukkonen and Leonard, 2013). For the receptor agonists, we might also expect other responses, like increased metabolic rate and peripheral responses; whether these were therapeutically useful for

other indications or detrimental as side effects remains to be shown.

An interesting feature of the multiple orexin receptor responses is their relation to the agonist concentration. This is most clearly seen in the recombinant OX₁ receptor-expressing CHO cells, in which different responses are triggered with distinct potencies spanning three orders of magnitude (Figure 3). Similar findings have also been reported in native OX₂-expressing AR42J cells (see *Endocrine and exocrine pancreas*). This could, most simply, be explained by response amplification differences obtained via mutual affinities and efficacies of the specific signal transduction cascade components and/or thresholds, but it may also require other processes like receptor dimerization or trafficking. Would such orexin peptide concentration dependence of the response also be seen in physiological context? This would open up interesting possibilities of completely different responses mediated by synaptic and extrasynaptic orexin receptors. Another aspect of orexin responses are the roles played by the functional orexin peptides orexin-A and orexin-B. The original studies in recombinant CHO cells presented an often-cited selectivity of OX₁ receptor between these peptides. While seen also in many other recombinant cell types with respect to Ca²⁺ elevation or PLC activation, this does not hold true for other responses (Kukkonen, 2013). We would thus like to suggest that orexin peptides display *biased agonism* (Kenakin, 2011), that is, that different agonists, like the endogenous orexin peptides, may preferentially activate different receptor responses. This could be further complicated by each receptor subtype having a different bias, and homo-oligomerization among orexin receptor 'monomers' or hetero-oligomerization with other GPCRs could affect these response profiles as well. Finally, if orexin-A and orexin-B were released together, their time courses of action could differ according to their relative stabilities (Yoshida *et al.*, 2003). In native cells, there are some dramatic examples of orexin-B being more potent or efficacious than orexin-A. As this has not been observed in any recombinant receptor expression system (with exception of Tang *et al.*, 2008), it raises the question of whether it is brought about by *biased agonism* (via receptor monomers or oligomers), or if there are one or more additional receptors for orexin peptides or if some other pharmacodynamic and pharmacokinetic properties of these peptides are involved?

In conclusion, studies with both recombinant and native cells support the view that orexin receptors are able to regulate many physiologically important molecular signalling cascades, but that not all cells utilize all possible cascades and that these cascades in native cells are not necessarily activated with the same efficacy as in recombinant systems. While it is clear that orexin signalling is diverse in the brain, future studies are needed to narrow the gap between what is known there and in recombinant systems. Advances in this area should benefit from the application of available pharmacological and molecular biological tools and knowledge of signalling patterns in recombinant systems. Finally, what regulates how orexin receptors (and other GPCRs) select a particular signalling pathway from all possible pathways at different sites is not known and is expected to be an important topic for future investigations.

Acknowledgements

This study was supported by the Academy of Finland (J. P. K.), the Magnus Ehrnrooth Foundation (J. P. K.), the Liv & Hälsa Foundation (J. P. K.) and grants NS027881 and HL064150 from the NIH of the USPHS (C. S. L.).

Conflicts of interest

None.

References

- Acuna-Goycolea C, van den Pol AN (2009). Neuroendocrine proopiomelanocortin neurons are excited by hypocretin/orexin. *J Neurosci* 29: 1503–1513.
- Adamantidis AR, Zhang F, Aravanis AM, Deisseroth K, de Lecea L (2007). Neural substrates of awakening probed with optogenetic control of hypocretin neurons. *Nature* 450: 420–424.
- Aghajanian GK, Vandermaelen CP (1982). Intracellular recordings from serotonergic dorsal raphe neurons: pacemaker potentials and the effect of LSD. *Brain Res* 238: 463–469.
- Ammoun S, Holmqvist T, Shariatmadari R, Oonk HB, Detheux M, Parmentier M *et al.* (2003). Distinct recognition of OX1 and OX2 receptors by orexin peptides. *J Pharmacol Exp Ther* 305: 507–514.
- Ammoun S, Johansson L, Ekholm ME, Holmqvist T, Danis AS, Korhonen L *et al.* (2006a). OX1 orexin receptors activate extracellular signal-regulated kinase (ERK) in CHO cells via multiple mechanisms: the role of Ca^{2+} influx in OX1 receptor signaling. *Mol Endocrinol* 20: 80–99.
- Ammoun S, Lindholm D, Wootz H, Åkerman KE, Kukkonen JP (2006b). G-protein-coupled OX1 orexin/hcrtr-1 hypocretin receptors induce caspase-dependent and -independent cell death through p38 mitogen-/stress-activated protein kinase. *J Biol Chem* 281: 834–842.
- Andrade R, Foehring RC, Tzingounis AV (2012). The calcium-activated slow AHP: cutting through the Gordian knot. *Front Cell Neurosci* 6: 47.
- Arrigoni E, Mochizuki T, Scammell TE (2010). Activation of the basal forebrain by the orexin/hypocretin neurones. *Acta Physiol (Oxf)* 198: 223–235.
- Baimel C, Borgland SL (2012). Hypocretin modulation of drug-induced synaptic plasticity. *Prog Brain Res* 198: 123–131.
- Barreiro ML, Pineda R, Navarro VM, Lopez M, Suominen JS, Pinilla L *et al.* (2004). Orexin 1 receptor messenger ribonucleic acid expression and stimulation of testosterone secretion by orexin-A in rat testis. *Endocrinology* 145: 2297–2306.
- Barreiro ML, Pineda R, Gaytan F, Archanco M, Burrell MA, Castellano JM *et al.* (2005). Pattern of orexin expression and direct biological actions of orexin-A in rat testis. *Endocrinology* 146: 5164–5175.
- Bayer L, Eggermann E, Serafin M, Saint-Mieux B, Machard D, Jones B *et al.* (2001). Orexins (hypocretins) directly excite tuberomammillary neurons. *Eur J Neurosci* 14: 1571–1575.
- Bayer L, Eggermann E, Saint-Mieux B, Machard D, Jones BE, Muhlethaler M *et al.* (2002). Selective action of orexin (hypocretin) on nonspecific thalamocortical projection neurons. *J Neurosci* 22: 7835–7839.
- Bayer L, Serafin M, Eggermann E, Saint-Mieux B, Machard D, Jones BE *et al.* (2004). Exclusive postsynaptic action of hypocretin-orexin on sublayer 6b cortical neurons. *J Neurosci* 24: 6760–6764.
- Bisetti A, Cveticovic V, Serafin M, Bayer L, Machard D, Jones BE *et al.* (2006). Excitatory action of hypocretin/orexin on neurons of the central medial amygdala. *Neuroscience* 142: 999–1004.
- Boissard R, Gervasoni D, Schmidt MH, Barbagli B, Fort P, Luppi PH (2002). The rat ponto-medullary network responsible for paradoxical sleep onset and maintenance: a combined microinjection and functional neuroanatomical study. *Eur J Neurosci* 16: 1959–1973.
- Borgland SL, Taha SA, Sarti F, Fields HL, Bonci A (2006). Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. *Neuron* 49: 589–601.
- Borgland SL, Storm E, Bonci A (2008). Orexin B/hypocretin 2 increases glutamatergic transmission to ventral tegmental area neurons. *Eur J Neurosci* 28: 1545–1556.
- Brown RE, Sergeeva O, Eriksson KS, Haas HL (2001). Orexin A excites serotonergic neurons in the dorsal raphe nucleus of the rat. *Neuropharmacology* 40: 457–459.
- Brown RE, Sergeeva OA, Eriksson KS, Haas HL (2002). Convergent excitation of dorsal raphe serotonin neurons by multiple arousal systems (orexin/hypocretin, histamine and noradrenaline). *J Neurosci* 22: 8850–8859.
- Brown RE, Winston S, Basheer R, Thakkar MM, McCarley RW (2006). Electrophysiological characterization of neurons in the dorsolateral pontine rapid-eye-movement sleep induction zone of the rat: intrinsic membrane properties and responses to carbachol and orexins. *Neuroscience* 143: 739–755.
- Brown RE, McKenna JT, Winston S, Basheer R, Yanagawa Y, Thakkar MM *et al.* (2008). Characterization of GABAergic neurons in rapid-eye-movement sleep controlling regions of the brainstem reticular formation in GAD67-green fluorescent protein knock-in mice. *Eur J Neurosci* 27: 352–363.
- Brown RE, Basheer R, McKenna JT, Strecker RE, McCarley RW (2012). Control of sleep and wakefulness. *Physiol Rev* 92: 1087–1187.
- Burdakov D, Liss B, Ashcroft FM (2003). Orexin excites GABAergic neurons of the arcuate nucleus by activating the sodium–calcium exchanger. *J Neurosci* 23: 4951–4957.
- Burdakov D, Jensen LT, Alexopoulos H, Williams RH, Fearon IM, O'Kelly I *et al.* (2006). Tandem-pore K^{+} channels mediate inhibition of orexin neurons by glucose. *Neuron* 50: 711–722.
- Burlet S, Tyler CJ, Leonard CS (2002). Direct and indirect excitation of laterodorsal tegmental neurons by hypocretin/orexin peptides: implications for wakefulness and narcolepsy. *J Neurosci* 22: 2862–2872.
- Carter ME, Borg JS, de Lecea L (2009). The brain hypocretins and their receptors: mediators of allostatic arousal. *Curr Opin Pharmacol* 9: 39–45.
- Chen C, Xu R (2003). The *in vitro* regulation of growth hormone secretion by orexins. *Endocrine* 22: 57–66.
- Chen J, Randevara HS (2004). Genomic organization of mouse orexin receptors: characterization of two novel tissue-specific splice variants. *Mol Endocrinol* 18: 2790–2804.

- Chen J, Karteris E, Collins D, Randeva HS (2006). Differential expression of mouse orexin receptor type-2 (OX2R) variants in the mouse brain. *Brain Res* 1103: 20–24.
- Chen XW, Huang W, Yan JA, Fan HX, Guo N, Lu J *et al.* (2008a). Reinvestigation of the effect of orexin A on catecholamine release from adrenal chromaffin cells. *Neurosci Lett* 436: 181–184.
- Chen XW, Mu Y, Huang HP, Guo N, Zhang B, Fan SY *et al.* (2008b). Hypocretin-1 potentiates NMDA receptor-mediated somatodendritic secretion from locus ceruleus neurons. *J Neurosci* 28: 3202–3208.
- Clapham DE (2003). TRP channels as cellular sensors. *Nature* 426: 517–524.
- Davis SF, Williams KW, Xu W, Glatzer NR, Smith BN (2003). Selective enhancement of synaptic inhibition by hypocretin (orexin) in rat vagal motor neurons: implications for autonomic regulation. *J Neurosci* 23: 3844–3854.
- Dergacheva O, Wang X, Huang ZG, Bouairi E, Stephens C, Gorini C *et al.* (2005). Hypocretin-1 (orexin-A) facilitates inhibitory and diminishes excitatory synaptic pathways to cardiac vagal neurons in the nucleus ambiguus. *J Pharmacol Exp Ther* 314: 1322–1327.
- Dergacheva O, Bateman R, Byrne P, Mendelowitz D (2012). Orexinergic modulation of GABAergic neurotransmission to cardiac vagal neurons in the brain stem nucleus ambiguus changes during development. *Neuroscience* 209: 12–20.
- Digby JE, Chen J, Tang JY, Lehnert H, Matthews RN, Randeva HS (2006). Orexin receptor expression in human adipose tissue: effects of orexin-A and orexin-B. *J Endocrinol* 191: 129–136.
- DiPolo R, Beauge L (2006). Sodium/calcium exchanger: influence of metabolic regulation on ion carrier interactions. *Physiol Rev* 86: 155–203.
- Doroshenko P, Renaud LP (2009). Acid-sensitive TASK-like K⁺ conductances contribute to resting membrane potential and to orexin-induced membrane depolarization in rat thalamic paraventricular nucleus neurons. *Neuroscience* 158: 1560–1570.
- Eggermann E, Serafin M, Bayer L, Machard D, Saint-Mieux B, Jones BE *et al.* (2001). Orexins/hypocretins excite basal forebrain cholinergic neurones. *Neuroscience* 108: 177–181.
- Ekholm ME, Johansson L, Kukkonen JP (2007). IP(3)-independent signalling of OX(1) orexin/hypocretin receptors to Ca(2+) influx and ERK. *Biochem Biophys Res Commun* 353: 475–480.
- El Firar A, Voisin T, Rouyer-Fessard C, Ostuni MA, Couvineau A, Laburthe M (2009). Discovery of a functional immunoreceptor tyrosine-based switch motif in a 7-transmembrane-spanning receptor: role in the orexin receptor OX1R-driven apoptosis. *FASEB J* 23: 4069–4080.
- Ellis J, Pediani JD, Canals M, Milasta S, Milligan G (2006). Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. *J Biol Chem* 281: 38812–38824.
- Eriksson KS, Sergeeva O, Brown RE, Haas HL (2001). Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. *J Neurosci* 21: 9273–9279.
- Follwell MJ, Ferguson AV (2002). Cellular mechanisms of orexin actions on paraventricular nucleus neurones in rat hypothalamus. *J Physiol* 545: 855–867.
- Ghosh M, Tucker DE, Burchett SA, Leslie CC (2006). Properties of the group IV phospholipase A2 family. *Prog Lipid Res* 45: 487–510.
- Girault EM, Yi CX, Fliers E, Kalsbeek A (2012). Orexins, feeding, and energy balance. *Prog Brain Res* 198: 47–64.
- Göncz E, Strowski MZ, Grotzinger C, Nowak KW, Kaczmarek P, Sassek M *et al.* (2008). Orexin-A inhibits glucagon secretion and gene expression through a Foxo1-dependent pathway. *Endocrinology* 149: 1618–1626.
- Govindaiah G, Cox CL (2006). Modulation of thalamic neuron excitability by orexins. *Neuropharmacology* 51: 414–425.
- Grabauskas G, Moises HC (2003). Gastrointestinal-projecting neurones in the dorsal motor nucleus of the vagus exhibit direct and viscerotopically organized sensitivity to orexin. *J Physiol* 549: 37–56.
- Grudt TJ, van den Pol AN, Perl ER (2002). Hypocretin-2 (orexin-B) modulation of superficial dorsal horn activity in rat. *J Physiol* 538: 517–525.
- Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S *et al.* (1999). Orexin A activates locus coeruleus cell firing and increases arousal in the rat. *Proc Natl Acad Sci U S A* 96: 10911–10916.
- Haj-Dahmane S, Shen RY (2005). The wake-promoting peptide orexin-B inhibits glutamatergic transmission to dorsal raphe nucleus serotonin neurons through retrograde endocannabinoid signaling. *J Neurosci* 25: 896–905.
- Harris DM, Go VL, Reeve JR, Jr, Wu SV (2002). Stimulation of amylase release by orexin is mediated by orexin 2 receptor in AR42J cells. *Pancreas* 25: 405–410.
- Ho YC, Lee HJ, Tung LW, Liao YY, Fu SY, Teng SF *et al.* (2011). Activation of orexin 1 receptors in the periaqueductal gray of male rats leads to antinociception via retrograde endocannabinoid (2-arachidonoylglycerol)-induced disinhibition. *J Neurosci* 31: 14600–14610.
- Hoang QV, Bajic D, Yanagisawa M, Nakajima S, Nakajima Y (2003). Effects of orexin (hypocretin) on GIRK channels. *J Neurophysiol* 90: 693–702.
- Hoang QV, Zhao P, Nakajima S, Nakajima Y (2004). Orexin (hypocretin) effects on constitutively active inward rectifier K⁺ channels in cultured nucleus basalis neurons. *J Neurophysiol* 92: 3183–3191.
- Holmqvist T, Åkerman KEO, Kukkonen JP (2002). Orexin signaling in recombinant neuron-like cells. *FEBS Lett* 526: 11–14.
- Holmqvist T, Johansson L, Östman M, Ammoun S, Åkerman KE, Kukkonen JP (2005). OX1 orexin receptors couple to adenylyl cyclase regulation via multiple mechanisms. *J Biol Chem* 280: 6570–6579.
- Horvath TL, Peyron C, Diano S, Ivanov A, Aston-Jones G, Kilduff TS *et al.* (1999). Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. *J Comp Neurol* 415: 145–159.
- Huang H, Ghosh P, van den Pol AN (2006). Prefrontal cortex-projecting glutamatergic thalamic paraventricular nucleus-excited by hypocretin: a feedforward circuit that may enhance cognitive arousal. *J Neurophysiol* 95: 1656–1668.
- Huang SC, Dai YW, Lee YH, Chiou LC, Hwang LL (2010). Orexins depolarize rostral ventrolateral medulla neurons and increase arterial pressure and heart rate in rats mainly via orexin 2 receptors. *J Pharmacol Exp Ther* 334: 522–529.
- Hwang LL, Chen CT, Dun NJ (2001). Mechanisms of orexin-induced depolarizations in rat dorsal motor nucleus of vagus neurones *in vitro*. *J Physiol* 537: 511–520.
- Ishibashi M, Takano S, Yanagida H, Takatsuna M, Nakajima K, Oomura Y *et al.* (2005). Effects of orexins/hypocretins on neuronal activity in the paraventricular nucleus of the thalamus in rats *in vitro*. *Peptides* 26: 471–481.

- Ishibashi M, Gumenchuk I, Leonard CS (2012). Orexin-A enhances a slow afterhyperpolarization (sAHP) and slows steady firing in serotonergic dorsal raphe (DR) neurons. *Neuroscience* 2012; New Orleans, LA. Society for Neuroscience: Washington, DC. Program No. 486.28.
- Ivanov A, Aston-Jones G (2000). Hypocretin/orexin depolarizes and decreases potassium conductance in locus coeruleus neurons. *Neuroreport* 11: 1755–1758.
- Jääntti MH, Putula J, Somerharju P, Frohman MA, Kukkonen JP (2012). OX(1) orexin/hypocretin receptor activation of phospholipase D. *Br J Pharmacol* 165: 1109–1123.
- Jääntti MH, Putula J, Turunen PM, Näsman J, Reijonen S, Kukkonen JP (2013). Autocrine endocannabinoid signaling potentiates orexin receptor signaling upon CB1 cannabinoid-OX1 orexin receptor coexpression. *Mol Pharmacol* 83: 621–632.
- Johansson L, Ekholm ME, Kukkonen JP (2007). Regulation of OX(1) orexin/hypocretin receptor-coupling to phospholipase C by Ca(2+) influx. *Br J Pharmacol* 150: 97–104.
- Johansson L, Ekholm ME, Kukkonen JP (2008). Multiple phospholipase activation by OX(1) orexin/hypocretin receptors. *Cell Mol Life Sci* 65: 1948–1956.
- Jöhren O, Neidert SJ, Kummer M, Dendorfer A, Dominiak P (2001). Prepro-orexin and orexin receptor mRNAs are differentially expressed in peripheral tissues of male and female rats. *Endocrinology* 142: 3324–3331.
- Jones BE (2005). From waking to sleeping: neuronal and chemical substrates. *Trends Pharmacol Sci* 26: 578–586.
- Karnani MM, Apergis-Schoute J, Adamantidis A, Jensen LT, de Lecea L, Fugger L *et al.* (2011). Activation of central orexin/hypocretin neurons by dietary amino acids. *Neuron* 72: 616–629.
- Karteris E, Randeve HS, Grammatopoulos DK, Jaffe RB, Hillhouse EW (2001). Expression and coupling characteristics of the CRH and orexin type 2 receptors in human fetal adrenals. *J Clin Endocrinol Metab* 86: 4512–4519.
- Karteris E, Chen J, Randeve HS (2004). Expression of human prepro-orexin and signaling characteristics of orexin receptors in the male reproductive system. *J Clin Endocrinol Metab* 89: 1957–1962.
- Karteris E, Machado RJ, Chen J, Zervou S, Hillhouse EW, Randeve HS (2005). Food deprivation differentially modulates orexin receptor expression and signalling in the rat hypothalamus and adrenal cortex. *Am J Physiol Endocrinol Metab* 288: E1089–E1100.
- Katayama Y, Homma T, Honda K, Hirai K (2003). Actions of orexin-A in the myenteric plexus of the guinea-pig small intestine. *Neuroreport* 14: 1515–1518.
- Kayaba Y, Nakamura A, Kasuya Y, Ohuchi T, Yanagisawa M, Komuro I *et al.* (2003). Attenuated defense response and low basal blood pressure in orexin knockout mice. *Am J Physiol Regul Integr Comp Physiol* 285: R581–R593.
- Kenakin T (1997). *Pharmacologic Analysis of Drug-Receptor Interaction*, 1st edn. Raven Press: New York.
- Kenakin T (2011). Functional selectivity and biased receptor signaling. *J Pharmacol Exp Ther* 336: 296–302.
- Kim J, Nakajima K, Oomura Y, Wayner MJ, Sasaki K (2009a). Electrophysiological effects of orexins/hypocretins on pedunculopontine tegmental neurons in rats: an *in vitro* study. *Peptides* 30: 191–209.
- Kim J, Nakajima K, Oomura Y, Wayner MJ, Sasaki K (2009b). Orexin-A and ghrelin depolarize the same pedunculopontine tegmental neurons in rats: an *in vitro* study. *Peptides* 30: 1328–1335.
- Kirchgessner AL, Liu M (1999). Orexin synthesis and response in the gut. *Neuron* 24: 941–951.
- Kohlmeier KA, Inoue T, Leonard CS (2004). Hypocretin/Orexin peptide signalling in the ascending arousal system: elevation of intracellular calcium in the mouse dorsal raphe and laterodorsal tegmentum. *J Neurophysiol* 92: 221–235.
- Kohlmeier KA, Watanabe S, Tyler CJ, Burlet S, Leonard CS (2008). Dual orexin actions on dorsal raphe and laterodorsal tegmentum neurons: noisy cation current activation and selective enhancement of Ca²⁺ transients mediated by L-type calcium channels. *J Neurophysiol* 100: 2265–2281.
- Kolaj M, Doroshenko P, Yan Cao X, Coderre E, Renaud LP (2007). Orexin-induced modulation of state-dependent intrinsic properties in thalamic paraventricular nucleus neurons attenuates action potential patterning and frequency. *Neuroscience* 147: 1066–1075.
- Kolaj M, Coderre E, Renaud LP (2008). Orexin peptides enhance median preoptic nucleus neuronal excitability via postsynaptic membrane depolarization and enhancement of glutamatergic afferents. *Neuroscience* 155: 1212–1220.
- Korotkova TM, Eriksson KS, Haas HL, Brown RE (2002). Selective excitation of GABAergic neurons in the substantia nigra of the rat by orexin/hypocretin *in vitro*. *Regul Pept* 104: 83–89.
- Korotkova TM, Sergeeva OA, Eriksson KS, Haas HL, Brown RE (2003). Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins/hypocretins. *J Neurosci* 23: 7–11.
- Kukkonen JP (2011). A ménage à trois made in heaven: G-protein-coupled receptors, lipids and TRP channels. *Cell Calcium* 50: 9–26.
- Kukkonen JP (2012). Recent progress in orexin/hypocretin physiology and pharmacology. *Biomol Concepts* 3: 447–463.
- Kukkonen JP (2013). Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. *Am J Physiol Cell Physiol* 301: C2–C32.
- Kukkonen JP, Åkerman KEO (2001). Orexin receptors couple to Ca²⁺ channels different from store-operated Ca²⁺ channels. *Neuroreport* 12: 2017–2020.
- Kukkonen JP, Leonard CS (2013). Orexin/hypocretin receptor signalling cascades. *Br J Pharmacol* (this issue).
- Lambe EK, Aghajanian GK (2003). Hypocretin (orexin) induces calcium transients in single spines postsynaptic to identified thalamocortical boutons in prefrontal slice. *Neuron* 40: 139–150.
- Larsson KP, Åkerman KEO, Magga J, Uotila S, Kukkonen JP, Näsman J *et al.* (2003). Orexin-A stimulates cholecystokinin release from intestinal neuroendocrine STC-1 cells by a Ca²⁺-dependent mechanism. *Biochem Biophys Res Commun* 309: 209–216.
- Larsson KP, Peltonen HM, Bart G, Louhivuori LM, Penttonen A, Antikainen M *et al.* (2005). Orexin-A-induced Ca²⁺ entry: evidence for involvement of TRPC channels and protein kinase C regulation. *J Biol Chem* 280: 1771–1781.
- de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE *et al.* (1998). The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. *Proc Natl Acad Sci U S A* 95: 322–327.
- Leonard CS, Kalogiannis M, Kohlmeier KA (2011). Hypocretin/orexin receptor functions in mesopontine systems regulating sleep, arousal and cataplexy. In: Baumann CR, Bassetti CL, Scammell TE (eds). *Narcolepsy: Pathophysiology, Diagnosis, and Treatment*. Springer: Berlin, pp. 139–152.
- Li B, Chen F, Ye J, Chen X, Yan J, Li Y *et al.* (2010). The modulation of orexin A on HCN currents of pyramidal neurons in mouse prelimbic cortex. *Cereb Cortex* 20: 1756–1767.

- Li H, de Lecea L (2013). The orexins as integrators of multiple physiological functions. *Br J Pharmacol* (this issue).
- Li Y, Gao XB, Sakurai T, van den Pol AN (2002). Hypocretin/Orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system. *Neuron* 36: 1169–1181.
- Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X *et al.* (1999). The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. *Cell* 98: 365–376.
- Liu M, Blanco-Centurion C, Konadhode R, Begum S, Pelluru D, Gerashchenko D *et al.* (2011). Orexin gene transfer into zona incerta neurons suppresses muscle paralysis in narcoleptic mice. *J Neurosci* 31: 6028–6040.
- Liu RJ, van den Pol AN, Aghajanian GK (2002). Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. *J Neurosci* 22: 9453–9464.
- Louhivuori LM, Jansson L, Nordstrom T, Bart G, Nasman J, Åkerman KE (2010). Selective interference with TRPC3/6 channels disrupts OX1 receptor signalling via NCX and reveals a distinct calcium influx pathway. *Cell Calcium* 48: 114–123.
- Lu J, Sherman D, Devor M, Saper CB (2006). A putative flip-flop switch for control of REM sleep. *Nature* 441: 589–594.
- Lund PE, Shariatmadari R, Uustare A, Detheux M, Parmentier M, Kukkonen JP *et al.* (2000). The orexin OX1 receptor activates a novel Ca^{2+} influx pathway necessary for coupling to phospholipase C. *J Biol Chem* 275: 30806–30812.
- Lungwitz EA, Molosh A, Johnson PL, Harvey BP, Dirks RC, Dietrich A *et al.* (2012). Orexin-A induces anxiety-like behavior through interactions with glutamatergic receptors in the bed nucleus of the stria terminalis of rats. *Physiol Behav* 107: 726–732.
- Luo CH, Rudy Y (1994). A dynamic model of the cardiac ventricular action potential. I. Simulations of ionic currents and concentration changes. *Circ Res* 74: 1071–1096.
- Ma X, Zubcevic L, Bruning JC, Ashcroft FM, Burdakov D (2007). Electrical inhibition of identified anorexigenic POMC neurons by orexin/hypocretin. *J Neurosci* 27: 1529–1533.
- Magee JC (1999). Dendritic Ih normalizes temporal summation in hippocampal CA1 neurons. *Nat Neurosci* 2: 508–514.
- Maggia J, Bart G, Oker-Blom C, Kukkonen JP, Åkerman KE, Nasman J (2006). Agonist potency differentiates G protein activation and Ca^{2+} signalling by the orexin receptor type 1. *Biochem Pharmacol* 71: 827–836.
- Malendowicz LK, Tortorella C, Nussdorfer GG (1999). Orexins stimulate corticosterone secretion of rat adrenocortical cells, through the activation of the adenylate cyclase-dependent signaling cascade. *J Steroid Biochem Mol Biol* 70: 185–188.
- Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M *et al.* (2001). Differential expression of orexin receptors 1 and 2 in the rat brain. *J Comp Neurol* 435: 6–25.
- Matsuo K, Kaibara M, Uezono Y, Hayashi H, Taniyama K, Nakane Y (2002). Involvement of cholinergic neurons in orexin-induced contraction of guinea pig ileum. *Eur J Pharmacol* 452: 105–109.
- Mazzocchi G, Malendowicz LK, Aragona F, Rebuffat P, Gottardo L, Nussdorfer GG (2001a). Human pheochromocytomas express orexin receptor type 2 gene and display an *in vitro* secretory response to orexins A and B. *J Clin Endocrinol Metab* 86: 4818–4821.
- Mazzocchi G, Malendowicz LK, Gottardo L, Aragona F, Nussdorfer GG (2001b). Orexin A stimulates cortisol secretion from human adrenocortical cells through activation of the adenylate cyclase-dependent signaling cascade. *J Clin Endocrinol Metab* 86: 778–782.
- Mieda M (2012). Differential regulation of non-REM and REM sleep by orexinergic neurons. *Neuroscience 2012*; New Orleans, LA. Society for Neuroscience: Washington, DC. Program No. 822.05.
- Mieda M, Willie JT, Hara J, Sinton CM, Sakurai T, Yanagisawa M (2004). Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. *Proc Natl Acad Sci U S A* 101: 4649–4654.
- Mieda M, Hasegawa E, Kisanuki YY, Sinton CM, Yanagisawa M, Sakurai T (2011). Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep. *J Neurosci* 31: 6518–6526.
- Mochizuki T, Arrigoni E, Marcus JN, Clark EL, Yamamoto M, Honer M *et al.* (2011). Orexin receptor 2 expression in the posterior hypothalamus rescues sleepiness in narcoleptic mice. *Proc Natl Acad Sci U S A* 108: 4471–4476.
- Mukai K, Kim J, Nakajima K, Oomura Y, Wayner MJ, Sasaki K (2009). Electrophysiological effects of orexin/hypocretin on nucleus accumbens shell neurons in rats: an *in vitro* study. *Peptides* 30: 1487–1496.
- Murai Y, Akaike T (2005). Orexins cause depolarization via nonselective cationic and K^{+} channels in isolated locus coeruleus neurons. *Neurosci Res* 51: 55–65.
- Muroya S, Funahashi H, Yamanaka A, Kohno D, Uramura K, Nambu T *et al.* (2004). Orexins (hypocretins) directly interact with neuropeptide Y, POMC and glucose-responsive neurons to regulate Ca^{2+} signaling in a reciprocal manner to leptin: orexigenic neuronal pathways in the mediobasal hypothalamus. *Eur J Neurosci* 19: 1524–1534.
- Nakabayashi M, Suzuki T, Takahashi K, Totsune K, Muramatsu Y, Kaneko C *et al.* (2003). Orexin-A expression in human peripheral tissues. *Mol Cell Endocrinol* 205: 43–50.
- Nakamura T, Uramura K, Nambu T, Yada T, Goto K, Yanagisawa M *et al.* (2000). Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. *Brain Res* 873: 181–187.
- Nakamura Y, Miura S, Yoshida T, Kim J, Sasaki K (2010). Cytosolic calcium elevation induced by orexin/hypocretin in granule cell domain cells of the rat cochlear nucleus *in vitro*. *Peptides* 31: 1579–1588.
- Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M, Goto K (1999). Distribution of orexin neurons in the adult rat brain. *Brain Res* 827: 243–260.
- Nanmoku T, Isobe K, Sakurai T, Yamanaka A, Takekoshi K, Kawakami Y *et al.* (2002). Effects of orexin on cultured porcine adrenal medullary and cortex cells. *Regul Pept* 104: 125–130.
- Näsman J, Bart G, Larsson K, Louhivuori L, Peltonen H, Åkerman KE (2006). The orexin OX1 receptor regulates Ca^{2+} entry via diacylglycerol-activated channels in differentiated neuroblastoma cells. *J Neurosci* 26: 10658–10666.
- Nattie E, Li A (2012). Respiration and autonomic regulation and orexin. *Prog Brain Res* 198: 25–46.
- Numata T, Kiyonaka S, Kato K, Takahashi N, Mori Y (2011). Activation of TRP channels in mammalian systems. In: Zhu MX (ed.). *TRP Channel*. CRC Press: Boca Raton, FL, pp. 43–90.
- Peltonen HM, Maggia JM, Bart G, Turunen PM, Antikainen MS, Kukkonen JP *et al.* (2009). Involvement of TRPC3 channels in

calcium oscillations mediated by OX(1) orexin receptors. *Biochem Biophys Res Commun* 385: 408–412.

Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG *et al.* (1998). Neurons containing hypocretin (orexin) project to multiple neuronal systems. *J Neurosci* 18: 9996–10015.

van den Pol AN (1999). Hypothalamic hypocretin (orexin): robust innervation of the spinal cord. *J Neurosci* 19: 3171–3182.

van den Pol AN, Gao XB, Obrietan K, Kilduff TS, Belousov AB (1998). Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin. *J Neurosci* 18: 7962–7971.

van den Pol AN, Patrylo PR, Ghosh PK, Gao XB (2001). Lateral hypothalamus: early developmental expression and response to hypocretin (orexin). *J Comp Neurol* 433: 349–363.

van den Pol AN, Ghosh PK, Liu RJ, Li Y, Aghajanian GK, Gao XB (2002). Hypocretin (orexin) enhances neuron activity and cell synchrony in developing mouse GFP-expressing locus coeruleus. *J Physiol* 541: 169–185.

Putula J, Kukkonen JP (2012). Mapping of the binding sites for the OX(1) orexin receptor antagonist, SB-334867, using orexin/hypocretin receptor chimaeras. *Neurosci Lett* 506: 111–115.

Putula J, Turunen PM, Jäntti MH, Ekholm ME, Kukkonen JP (2011). Agonist ligand discrimination by the two orexin receptors depends on the expression system. *Neurosci Lett* 494: 57–60.

Ramanjaneya M, Conner AC, Chen J, Stanfield PR, Randeve HS (2008). Orexins stimulate steroidogenic acute regulatory protein expression through multiple signaling pathways in human adrenal H295R cells. *Endocrinology* 149: 4106–4115.

Ramanjaneya M, Conner AC, Chen J, Kumar P, Brown JE, Johren O *et al.* (2009). Orexin-stimulated MAP kinase cascades are activated through multiple G-protein signalling pathways in human H295R adrenocortical cells: diverse roles for orexins A and B. *J Endocrinol* 202: 249–261.

Randeve HS, Karteris E, Grammatopoulos D, Hillhouse EW (2001). Expression of orexin-A and functional orexin type 2 receptors in the human adult adrenals: implications for adrenal function and energy homeostasis. *J Clin Endocrinol Metab* 86: 4808–4813.

Roecker AJ, Coleman PJ (2008). Orexin receptor antagonists: medicinal chemistry and therapeutic potential. *Curr Top Med Chem* 8: 977–987.

Rosker C, Graziani A, Lukas M, Eder P, Zhu MX, Romanin C *et al.* (2004). Ca(2+) signaling by TRPC3 involves Na(+) entry and local coupling to the Na(+)/Ca(2+) exchanger. *J Biol Chem* 279: 13696–13704.

Rouchet N, Waroux O, Lamy C, Massotte L, Scuvée-Moreau J, Liegeois JF *et al.* (2008). SK channel blockade promotes burst firing in dorsal raphe serotonergic neurons. *Eur J Neurosci* 28: 1108–1115.

Rouet-Benzineb P, Rouyer-Fessard C, Jarry A, Avondo V, Pouzet C, Yanagisawa M *et al.* (2004). Orexins acting at native OX(1) receptor in colon cancer and neuroblastoma cells or at recombinant OX(1) receptor suppress cell growth by inducing apoptosis. *J Biol Chem* 279: 45875–45886.

Routtenberg A (1996). Reverse piepiperase: is the knockout mouse leading neuroscientists to a watery end? *Trends Neurosci* 19: 471–472.

Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H *et al.* (1998). Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell* 92: 573–585.

Samson WK, Taylor MM (2001). Hypocretin/orexin suppresses corticotroph responsiveness in vitro. *Am J Physiol Regul Integr Comp Physiol* 281: R1140–R1145.

Selbach O, Doreulee N, Bohla C, Eriksson KS, Sergeeva OA, Poelchen W *et al.* (2004). Orexins/hypocretins cause sharp wave- and theta-related synaptic plasticity in the hippocampus via glutamatergic, gabaergic, noradrenergic, and cholinergic signaling. *Neuroscience* 127: 519–528.

Selbach O, Bohla C, Barbara A, Doreulee N, Eriksson KS, Sergeeva OA *et al.* (2010). Orexins/hypocretins control bistability of hippocampal long-term synaptic plasticity through co-activation of multiple kinases. *Acta Physiol (Oxf)* 198: 277–285.

Sellayah D, Bharaj P, Sikder D (2011). Orexin is required for brown adipose tissue development, differentiation, and function. *Cell Metab* 14: 478–490.

Sharf R, Sarhan M, Dileone RJ (2010). Role of orexin/hypocretin in dependence and addiction. *Brain Res* 1314: 130–138.

Shin HS, Cho HS, Sung KW, Yoon BJ (2009). Orexin-A increases cell surface expression of AMPA receptors in the striatum. *Biochem Biophys Res Commun* 378: 409–413.

Siegel JM, Boehmer LN (2006). Narcolepsy and the hypocretin system – where motion meets emotion. *Nat Clin Pract Neurol* 2: 548–556.

Skrzypski M, Le TT, Kaczmarek P, Pruszyńska-Oszmalek E, Pietrzak P, Szczepankiewicz D *et al.* (2011). Orexin A stimulates glucose uptake, lipid accumulation and adiponectin secretion from 3T3-L1 adipocytes and isolated primary rat adipocytes. *Diabetologia* 54: 1841–1852.

Skrzypski M, Kaczmarek P, Le TT, Wojciechowicz T, Pruszyńska-Oszmalek E, Szczepankiewicz D *et al.* (2012). Effects of orexin A on proliferation, survival, apoptosis and differentiation of 3T3-L1 preadipocytes into mature adipocytes. *FEBS Lett* 586: 4157–4164.

Smart D, Jerman JC, Brough SJ, Rushton SL, Murdock PR, Jewitt F *et al.* (1999). Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPR. *Br J Pharmacol* 128: 1–3.

Smith BN, Davis SF, Van Den Pol AN, Xu W (2002). Selective enhancement of excitatory synaptic activity in the rat nucleus tractus solitarius by hypocretin 2. *Neuroscience* 115: 707–714.

Soffin EM, Gill CH, Brough SJ, Jerman JC, Davies CH (2004). Pharmacological characterisation of the orexin receptor subtype mediating postsynaptic excitation in the rat dorsal raphe nucleus. *Neuropharmacology* 46: 1168–1176.

Squecco R, Garella R, Luciani G, Francini F, Baccari MC (2011). Muscular effects of orexin A on the mouse duodenum: mechanical and electrophysiological studies. *J Physiol* 589: 5231–5246.

Takahashi K, Koyama Y, Kayama Y, Yamamoto M (2002). Effects of orexin on the laterodorsal tegmental neurones. *Psychiatry Clin Neurosci* 56: 335–336.

Tang J, Chen J, Ramanjaneya M, Pun A, Conner AC, Randeve HS (2008). The signalling profile of recombinant human orexin-2 receptor. *Cell Signal* 20: 1651–1661.

van den Top M, Nolan MF, Lee K, Richardson PJ, Buijs RM, Davies CH *et al.* (2003). Orexins induce increased excitability and synchronisation of rat sympathetic preganglionic neurones. *J Physiol* 549: 809–821.

van den Top M, Lee K, Whyment AD, Blanks AM, Spanswick D (2004). Orexin-sensitive NPY/AgRP pacemaker neurons in the hypothalamic arcuate nucleus. *Nat Neurosci* 7: 493–494.

- Török TL (2007). Electrogenic $\text{Na}^+/\text{Ca}^{2+}$ -exchange of nerve and muscle cells. *Prog Neurobiol* 82: 287–347.
- Trivedi P, Yu H, MacNeil DJ, Van der Ploeg LH, Guan XM (1998). Distribution of orexin receptor mRNA in the rat brain. *FEBS Lett* 438: 71–75.
- Tsujino N, Yamanaka A, Ichiki K, Muraki Y, Kilduff TS, Yagami K *et al.* (2005). Cholecystokinin activates orexin/hypocretin neurons through the cholecystokinin A receptor. *J Neurosci* 25: 7459–7469.
- Turunen PM, Ekholm ME, Somerharju P, Kukkonen JP (2010). Arachidonic acid release mediated by OX(1) orexin receptors. *Br J Pharmacol* 159: 212–221.
- Turunen PM, Jäntti MH, Kukkonen JP (2012). OX1 orexin/hypocretin receptor signaling via arachidonic acid and endocannabinoid release. *Mol Pharmacol* 82: 156–167.
- Uramura K, Funahashi H, Muroya S, Shioda S, Takigawa M, Yada T (2001). Orexin-a activates phospholipase C- and protein kinase C-mediated Ca^{2+} signaling in dopamine neurons of the ventral tegmental area. *Neuroreport* 12: 1885–1889.
- Velimirovic BM, Koyano K, Nakajima S, Nakajima Y (1995). Opposing mechanisms of regulation of a G-protein-coupled inward rectifier K^+ channel in rat brain neurons. *Proc Natl Acad Sci U S A* 92: 1590–1594.
- Voisin T, Firar AE, Avondo V, Laburthe M (2006). Orexin-induced apoptosis: the key role of the seven-transmembrane domain orexin type 2 receptor. *Endocrinology* 147: 4977–4984.
- Voisin T, El Firar A, Rouyer-Fessard C, Gratio V, Laburthe M (2008). A hallmark of immunoreceptor, the tyrosine-based inhibitory motif ITIM, is present in the G protein-coupled receptor OX1R for orexins and drives apoptosis: a novel mechanism. *FASEB J* 22: 1993–2002.
- Voisin T, El Firar A, Fasseu M, Rouyer-Fessard C, Descatoire V, Walker F *et al.* (2011). Aberrant expression of OX1 receptors for orexins in colon cancers and liver metastases : an openable gate to apoptosis. *Cancer Res* 71: 3341–3351.
- Ward RJ, Pediani JD, Milligan G (2011). Ligand-induced internalization of the orexin OX(1) and cannabinoid CB(1) receptors assessed via N-terminal SNAP and CLIP-tagging. *Br J Pharmacol* 162: 1439–1452.
- Wenzel J, Grabinski N, Knopp CA, Dendorfer A, Ramanjaneya M, Randeva HS *et al.* (2009). Hypocretin/orexin increases the expression of steroidogenic enzymes in human adrenocortical NCI H295R cells. *Am J Physiol Regul Integr Comp Physiol* 297: R1601–R1609.
- Willie JT, Chemelli RM, Sinton CM, Tokita S, Williams SC, Kisanuki YY *et al.* (2003). Distinct narcolepsy syndromes in orexin receptor-2 and Orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes. *Neuron* 38: 715–730.
- Winrow CJ, Renger JJ (2013). Discovery and development of orexin receptor antagonists as therapeutics for insomnia. *Br J Pharmacol* (this issue).
- Wu M, Zhang Z, Leranath C, Xu C, van den Pol AN, Alreja M (2002). Hypocretin increases impulse flow in the septohippocampal GABAergic pathway: implications for arousal via a mechanism of hippocampal disinhibition. *J Neurosci* 22: 7754–7765.
- Wu M, Zaborszky L, Hajszan T, van den Pol AN, Alreja M (2004). Hypocretin/orexin innervation and excitation of identified septohippocampal cholinergic neurons. *J Neurosci* 24: 3527–3536.
- Xia J, Chen X, Song C, Ye J, Yu Z, Hu Z (2005). Postsynaptic excitation of prefrontal cortical pyramidal neurons by hypocretin-1/orexin A through the inhibition of potassium currents. *J Neurosci Res* 82: 729–736.
- Yamanaka A, Tsujino N, Funahashi H, Honda K, Guan JL, Wang QP *et al.* (2002). Orexins activate histaminergic neurons via the orexin 2 receptor. *Biochem Biophys Res Commun* 290: 1237–1245.
- Yamanaka A, Beuckmann CT, Willie JT, Hara J, Tsujino N, Mieda M *et al.* (2003). Hypothalamic orexin neurons regulate arousal according to energy balance in mice. *Neuron* 38: 701–713.
- Yamanaka A, Tabuchi S, Tsunematsu T, Fukazawa Y, Tominaga M (2010). Orexin directly excites orexin neurons through orexin 2 receptor. *J Neurosci* 30: 12642–12652.
- Yamuy J, Fung SJ, Xi M, Chase MH (2004). Hypocretinergic control of spinal cord motoneurons. *J Neurosci* 24: 5336–5345.
- Yan J, He C, Xia JX, Zhang D, Hu ZA (2012). Orexin-A excites pyramidal neurons in layer 2/3 of the rat prefrontal cortex. *Neurosci Lett* 520: 92–97.
- Yanagisawa M (2010). Small-molecule agonist for type-2 orexin receptor. USA.
- Yang B, Ferguson AV (2002). Orexin-A depolarizes dissociated rat area postrema neurons through activation of a nonselective cationic conductance. *J Neurosci* 22: 6303–6308.
- Yang B, Ferguson AV (2003). Orexin-A depolarizes nucleus tractus solitarius neurons through effects on nonselective cationic and K^+ conductances. *J Neurophysiol* 89: 2167–2175.
- Yang B, Samson WK, Ferguson AV (2003). Excitatory effects of orexin-A on nucleus tractus solitarius neurons are mediated by phospholipase C and protein kinase C. *J Neurosci* 23: 6215–6222.
- Yoshida Y, Fujiki N, Maki RA, Schwarz D, Nishino S (2003). Differential kinetics of hypocretins in the cerebrospinal fluid after intracerebroventricular administration in rats. *Neurosci Lett* 346: 182–186.
- Zeitler JM, Buckmaster CL, Lyons DM, Mignot E (2004). Locomotor-dependent and -independent components to hypocretin-1 (orexin A) regulation in sleep-wake consolidating monkeys. *J Physiol* 557: 1045–1053.
- Zhang J, Li B, Yu L, He YC, Li HZ, Zhu JN *et al.* (2011). A role for orexin in central vestibular motor control. *Neuron* 69: 793–804.
- Zhang L, Renaud LP, Kolaj M (2009). Properties of a T-type Ca^{2+} channel-activated slow afterhyperpolarization in thalamic paraventricular nucleus and other thalamic midline neurons. *J Neurophysiol* 101: 2741–2750.
- Zhang L, Kolaj M, Renaud LP (2010). Ca^{2+} -dependent and Na^+ -dependent K^+ conductances contribute to a slow AHP in thalamic paraventricular nucleus neurons: a novel target for orexin receptors. *J Neurophysiol* 104: 2052–2062.
- Zwirski-Korczala K, Adamczyk-Sowa M, Sowa P, Pilc K, Suchanek R, Pierzchala K *et al.* (2007). Role of leptin, ghrelin, angiotensin II and orexins in 3T3 L1 preadipocyte cells proliferation and oxidative metabolism. *J Physiol Pharmacol* 58 (Suppl. 1): 53–64.

Supporting information

Additional Supporting Information may be found in the online version of this article at the publisher's web-site:

<http://dx.doi.org/10.1111/bph.12296>

Table S1 Postsynaptic orexin actions in the CNS.